Probes and assays for calcium channel α2 subunit-encoding nucleic acids

ABSTRACT

Calcium channel (alpha) 1  -subunit and (alpha) 2  -subunit-encoding DNA, and related compositions and methods, are provided.

This application is a divisional of U.S. application Ser. No.07/914,231, filed Jul. 13, 1992, now U.S. Pat. No. 5,407,820, which is acontinuation of U.S. application Ser. No. 07/603,751, filed Nov. 8,1990, now abandoned, which is a continuation-in-part of U.S. applicationSer. No. 07/176,899, filed Apr. 4, 1988, now abandoned. U.S. applicationSer. No. 07/603,751 was filed as International PCT ApplicationPCT/US89/01408, on Apr. 4, 1989.

TECHNICAL FIELD

The present invention relates to molecular biology and pharmacology.

More particularly, the invention relates to calcium channel compositionsand methods of making and using same.

BACKGROUND OF THE INVENTION

Calcium channels are membrane-spanning, multisubunit proteins that allowcontrolled entry of Ca⁺² ions into cells from the extracellular fluid.All cells throughout the animal kingdom, and at least some bacterial,fungal and plant cells, possess one or more types of calcium channel.

The most common type of calcium channel is voltage-dependent. In avoltage-dependent channel, the "opening," to allow an influx of Ca⁺²ions into the cells to begin, requires a depolarization to a certainlevel of the potential difference between the inside of the cell bearingthe channel and the extracellular medium bathing the cell and the rateof influx of Ca⁺² into the cell depends on this potential difference.All "excitable" cells in animals, such as neurons of the central nervoussystems, peripheral nerve cells, and muscle cells, including those ofskeletal muscles, cardiac muscles, and venous and arterial smoothmuscles, have voltage-dependent calcium channels.

Calcium channels are physiologically important because the channels havea central role in regulating intracellular Ca⁺² levels and these levelsare important for cell viability and function. Thus, intracellular Ca⁺²concentrations are implicated in a number of vital processes in animals,such as neurotransmitter release, muscle contraction, pacemakeractivity, and secretion of hormones and other substances.

A number of compounds useful in treating various diseases in animals,including humans, are thought to exert their beneficial effects bymodulating functions of voltage-dependent calcium channels. Many ofthese compounds bind to calcium channels and block, or reduce the rateof, influx of Ca⁺² into cells in response to depolarization of theinside and outside of the cells.

An understanding of the pharmacology of compounds that interact withcalcium channels, and the ability to rationally design compounds thatwill interact with calcium channels to have desired therapeutic effects,have been hampered by a lack of understanding of the structure ofchannel subunits and the genes that code for them. Thus, it has not beenpossible to obtain the large amounts of highly purified channel subunitsthat are required to understand, at the molecular level, the nature ofthe subunits and their interactions with one another, with the cellmembranes across which the channels allow Ca⁺² ions to pass, with Ca⁺²and other ions, and with low molecular weight compounds that affectchannel function. For example, with the availability of large amounts ofpurified calcium channel subunits, functional channels could be preparedand used to screen the effects of compounds on channel function, therebyproviding a basis for the design of therapeutic agents which affect thecalcium channel, or various combinations of channel subunits could becrystallized and have their structures determined to high resolutionemploying X-ray or neutron diffraction techniques, providing yet anotherbasis for rational design of therapeutic agents that affect channelfunction.

Certain diseases, such as Lambert-Eaton Syndrome, involve autoimmuneinteractions with calcium channels. The ready availability of calciumchannel subunits would make possible immunoassays for the diagnosis ofsuch diseases and an understanding of them at the molecular level thatcould lead to effective methods for treating them.

The lack of information on genes that code for calcium channel subunitshas prevented the understanding of the molecular properties of themature calcium channel subunits and their precursor proteins (i.e., themature subunits with signal peptides appended to the amino-terminus) andthe regulation of expression of calcium channel subunits. Anunderstanding of these properties, and of how expression of calciumchannel subunit genes is regulated, may provide the basis for designingtherapeutic agents which have beneficial effects through affectingcalcium channel function or concentration Furthermore, the availabilityof sequences of genes coding for calcium channel subunits would makepossible the diagnosis of defects, which might underlie a number ofdiseases, in genes coding for such subunits.

The availability of a DNA with the sequence of a segment, of at leastabout 12, and more preferably at least about 30, nucleotides of a cDNAencoding a subunit of a calcium channel from the cells of a tissue of ananimal would make possible the isolation and cloning of cDNA's, andpossibly genomic DNA's, coding for the corresponding subunit ofdifferent calcium channels from the same or different tissues andanimals of the same or different species. The availability of thesequences of numerous full-length cDNA's coding for correspondingsubunits of calcium channels from a variety of tissues and animalspecies would contribute to elucidating structure-function relationshipsin the subunits and this knowledge, in turn, would be useful in thedesign of therapeutic agents whose activities are exerted throughbinding to calcium channels.

Voltage-dependent calcium channels are thought to consist of two largesubunits, of between about 130 and about 200 kilodaltons ("kD") inmolecular weight, and a number (generally thought to be one or three) ofdifferent smaller subunits, of less than about 60 kD in molecularweight. At least one of the larger subunits and possibly some of thesmaller are glycosylated. Some of the subunits are capable of beingphosphorylated. There is confusion in the art concerning the naming ofthe various subunits of voltage-dependent calcium channels.

The two large subunits of voltage-dependent calcium channels aredesignated herein the "(alpha)₁ -subunit" and the "(alpha)₂ -subunit".

The (alpha)₁ -subunit is not detectably changed in molecular weight whentreated with dithiothreitol ("DTT") or with enzymes which catalyzeremoval of N-linked sugar groups from glycosylated proteins. The(alpha)₁ -subunit has a molecular weight of about 150 to about 170 kDwhen analyzed by sodium dodecylsulfate ("SDS")-polyacrylamide gelelectrophresis ("PAGE") after isolation from mammalian muscle tissue andhas specific binding sites for various 1,4-dihydropyridines ("DHPs") andphenylalkylamines.

The (alpha)₂ -subunit is somewhat less well characterized than the(alpha)₁ -subunit. The molecular weight of the (alpha)₂ -subunit As atleast about 130-150 kD, as determined by SDS-PAGE analysis in thepresence of DTT after isolation from mammalian muscle tissue. However,in SDS-PAGE under non-reducing conditions (in the presence ofN-ethylmaleimide), the (alpha)₂ -subunit migrates with a band of about160-190 kD. It is not known in the art whether the smaller fragment (ofabout 30 kD), which appears to be released upon reduction, is theproduct of a gene different from the gene which encodes the 130-150 kDfragment (and, consequently, the two fragments are different subunits ofthe calcium channel) or whether both fragments are products of the samegenes (and, consequently, the (alpha)₂ -subunit is about 160-190 kD andis split into (at least) two fragments upon reduction). There isevidence that the (alpha)₂ -subunit, whatever its size, and thecorresponding fragment produced under reducing conditions, whether partof the (alpha)₂ -subunit or not, are glycosylated with at least N-linkedsugars and do not have specified binding sites for 1,4-dihydropyridinesand phenylalkylamines that are known to bind to the (alpha)₁ -subunit.

Reference herein to the precursor of an (alpha)₁ -subunit means theprotein with the amino acid sequence corresponding to the sequence ofthe full-length mRNA which, upon translation, results, ultimately, in(alpha)₁ -subunit resident as part of a calcium channel in a cellmembrane. The precursor protein is convened by various processing stepsinto the (alpha)₁ -subunit. The details of the processing between theprecursor and the mature (alpha)₁ -subunit are not clear, but theprocessing possibly involves phosphorylation and also cleavage of theprimary translation product to yield the mature (alpha)₁ -subunit of thecalcium channel.

Similarly, reference herein to the precursor of an (alpha)₂ -subunitmeans the protein with the amino acid sequence corresponding to thesequence of the full-length mRNA which, upon translation, results,ultimately, in (alpha)₂ -subunit resident as part of a calcium channelin a cell membrane. The precursor protein is converted by variousprocessing steps into the (alpha)₂ -subunit. As with the (alpha)₁-subunit, the details of the processing between the precursor and themature (alpha)₂ -subunit are not clear, but the processing presumablyinvolves at least removal of a leader sequence (i.e., a signal peptide),glycosylation, and, possibly, cleavage to yield what are now thought tobe other subunits of the calcium channel.

The cDNA and corresponding amino acid sequence of the (alpha)₁ -subunitprecursor of a rabbit back skeletal muscle calcium channel has beenreported. Tanabe et al., Nature 328, 313-318 (1987).

Calcium channel activity, measured electrophysiologically byvoltage-clamp techniques, has been induced in Xenopus laevis oocyteswhen total mRNA isolated from mammalian brain and cardiac muscle isinjected into the oocytes. Also, it has been reported that calciumchannel-containing preparations, when reconstituted into lipid bilayers,confer voltage-dependent calcium channel activity on the bilayers.

However, there is no evidence that the (alpha)₁ -subunit alone or the(alpha)₂ -subunit alone provides a functional calcium channel inoocytes, lipid bilayers or any other situation. It has been recentlyreported by Hofmann, et al., Trends in Pharmacolog. Sci. 8, 393-398(1987) that mRNA prepared using the cDNA of (alpha)₁ -subunit obtainedby Tanabe, et al. was unable to induce calcium channel activity inXenopus laevis oocytes.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1a-1j set forth the nucleotide sequence of the cDNA encoding the(alpha)₁ -subunit of the rabbit skeletal calcium channel (SEQ ID NO: 1)and the amino acid sequence encoded by the 5,619 nucleotide open readingframe, which encodes a sequence of 1,873 amino acids. The 3' non-codingsequence of the cDNA is 234 nucleotides in length, excluding the poly(dA) tract, and contains a consensus polyadenylation signal ATTAAA(nucleotides 5832-5837) 17 nucleotides upstream from the poly (dA)tract.

FIGS. 2a-2f set forth the 3,802 nucleotide and amino acid sequences ofthe rabbit skeletal calcium channel (alpha)₂ -subunit (SEQ ID NO: 2).The figure includes the nucleotides of the cDNA that encodes the(alpha)₂ -subunit precursor, including the 308 nucleotides of the 5'untranslated sequence, the 3,318 nucleotide open reading frame and 176nucleotides of 3' untranslated sequence. The signal peptide of the(alpha)₂ -subunit is shown as the first 26 negatively numbered aminoacids.

FIGS. 3a-3d compare the sequences of the DNA encoding the human neuronalα₂ -subunit (SEQ 10 NO: 3) with that encoding the rabbit skeletal α₂-subunit.

The boxes in the figures enclose transmembrane regions. The symbol, P,denotes a phosphorylation site and the symbol, *, indicates aN-glycosylation site.

DETAILED DESCRIPTION OF THE INVENTION

In short, we have discovered a cDNA which codes for the (alpha)₁-subunit of an animal calcium channel (see FIGS. 1a-1j) and a cDNA whichcodes for the (alpha)₂ -subunit of an animal calcium channel (see FIGS.2a-2f and Example 4).

Thus in one of its aspects, the invention is a DNA which comprises acDNA which codes for the (alpha)₂ -subunit of an animal calcium channel,and the RNA, coding for such a subunit, made upon transcription of sucha DNA according to the invention.

In another of its aspects, the invention is a substantially pure(alpha)₂ -subunit of an animal calcium channel.

By a "substantially pure" subunit or protein is meant a subunit orprotein that is sufficiently free of other polypeptide contaminants tobe considered homogeneous by SDS-PAGE or to be unambiguously sequenced.

In another of its aspects, the invention entails an eukaryotic cell withan heterologous calcium channel, said cell made by a process comprisingadministering to said cell a first composition, which consistsessentially of a first RNA which is translatable in said cell into theprecursor of the (alpha)₁ -subunit of a calcium channel of an animal ofa first species, and a second composition which consists essentially ofa second RNA which is translatable in said cell into the precursor ofthe (alpha)₂ -subunit of a calcium channel of an animal of a secondspecies, said first and second species being the same or different,provided that at least one of said precursor of said (alpha)₁ -subunitand said precursor of said (alpha)₂ -subunit is foreign to said cell.Preferred cells for this purpose are Xenopus laevis oocytes.

In another of its aspects, the invention entails a method for assaying acompound for calcium channel agonist or antagonist activity whichcomprises electrophysiologically measuring the calcium channel activityof a cell described in the immediately preceeding paragraph when suchcell is exposed to a solution of the compound being tested for suchactivity. For similar methods applied with Xenopus laevis oocytes andacetylcholine receptors, see e.g., Mishina et al. Nature 313, 364 (1985)and, with such oocytes and sodium channels, see Noda et al., Nature 322,826-828 (1986).

In a further of its aspects, the invention is an eukaryotic cellcontaining a DNA which comprises a cDNA which can be expressed to makethe (alpha)₂ -subunit of a calcium channel. Such a cell according to theinvention can also contain a DNA which comprises a cDNA which can beexpressed to make the (alpha)₁ -subunit of a calcium channel.Preferably, the (alpha)₂ -subunit or the (alpha)₁ -subunit made fromsuch a cDNA in such a cell will be foreign to the cell, i.e., will havean amino acid sequence which differs from that of any calcium channel(alpha)₁ -subunit or (alpha)₂ -subunit which occurs in a cell of thesame type which does not contain a DNA from which the (alpha)₁ -subunitor the (alpha)₂ -subunit encoded by such a cDNA is expressed. Preferredamong such cells are those of mammalian origin, such as COS cells,NIH3T3 cells, mouse L cells or the like, or those of yeast such as S.cerevisiae or P. pastoris. Methods of making such cells of theinvention, by transforming cells with suitable heterologous DNAs, to bemaintained in the cell as episomes or (preferably) integrated intochromosomal DNA of the cell, and then culturing transformants orsubculturing (or passaging, in the case of mammalian cells) from such aculture or a subculture thereof, are well known to those of ordinaryskill.

Among such cells of the invention, the invention entails also aneukaryotic cell with an heterologous calcium channel, said calciumchannel made by a process comprising expression of a first cDNA, whichcodes for the precursor of the (alpha)₁ -subunit of a calcium channel ofan animal of a first species, and a second cDNA, which codes for theprecursor of the (alpha)₂ -subunit of a calcium channel of a secondspecies, said first and second species being the same or different.Usually at least one of said precursor of said (alpha)₁ -subunit andsaid precursor of said (alpha)₂ -subunit is foreign to said cell. Again,preferred among such cells are those of mammalian origin or those ofyeast such as S. cerevisiae cells or P. pastoris. In a preferredembodiment, such a cell will also contain another heterologous gene,which comprises a transcriptional control element (e.g., a promoter orpromoter/enhancer combination), which is active in said cell and thetranscriptional activity of which responds to an ion or molecule capableof entering said cell through a functional calcium channel (e.g., Ca⁺⁺,Ba⁺⁺, Ca⁺⁺ ionophores), linked operatively for expression to astructural gene for an indicator protien, such a chloramphenicolacetyltransferase, luciferase or β-galactosidase.

These cells of the invention, which have functional, foreign calciumchannels (i.e., functional calcium channels wherein at least one of the(alpha)₁ -subunit and the (alpha)₂ -subunit is foreign to the cell) willbe useful for, among other purposes, assaying a compound for calciumchannel agohist'or antagonist activity. First, such a cell can beemployed to measure the affinity of such a compound for the functionalcalcium channel. Secondly, such a cell can be employed to measureelectrophysiologically the calcium channel activity in the presence ofthe compound being tested as well as a ion or molecule, such as Ca⁺⁺ orBa⁺⁺, which is known to be capable of entering the cell through thefunctional channel. For similar studies which have been carried out withthe acetylcholine receptor, see Claudio et al. Science 238 1688-1694(1987). These methods for assaying a compound for calcium channelagohist or antagonist activity are also part of the present invention.

Such cells according to the invention, in the preferred embodiment,wherein the cell also contains an heterologous gene with atranscriptional control element, which is active in the cell andresponsive to an ion or molecule capable of entering the cell through afunctional calcium channel and is linked operatively for expression to astructural gene for an indicator protein, can also be employed, inanother method according to the invention for assaying a compound forcalcium channel agohist or antagonist activity. This method comprisesexposing a culture of such cells to a solution of a compound beingtested for such activity, together with an ion or molecule, which iscapable of entering the cells through a functional calcium channel andaffecting the activity of the transcriptional control elementcontrolling transcription of the gene for the indicator protein, andcomparing the level of expression, in the cells of the culture, of thegene for the indicator protein with the level of such expression in thecells of another, control culture of such cells.

A "control culture," as clearly understood by the skilled, will be aculture that is, and is treated, substantially the same as the cultureexposed to the compound being assayed except that the control culture isnot exposed to the compound being assayed. Levels of expression of thegenes for the indicator proteins are ascertained readily by the skilledby known methods, which involve measurements of the concentration ofindicator protein via assays for detectable compounds produced inreactions catalyzed by the indicator protein.

As indicated above, indicator proteins are enzymes which are active inthe cells of the invention and catalyze production of readily detectablecompounds (e.g., chromogens, fluorescent compounds).

In a still further aspect, the invention is a method for diagnosingLambert-Eaton Syndrome in a person by immunoassay which method comprisescombining serum from the person with (alpha)₁ -subunit of a first animalspecies and (alpha)₂ -subunit of a second animal species (the same as ordifferent from the first species) and ascertaining whether antibodies inthe serum react with one or both of the subunits to a greater extentthan antibodies in control serum (e.g., from a person or group ofpersons known to be free of the Syndrome). Any immunoassay procedureknown in the art for detecting antibodies in serum against a givenantigen can be employed in the method. Preferably, in the method, bothof the (alpha) subunits are from a mammalian calcium channel, mostpreferably human.

The invention entails also a labeled (e.g., ³² P or a biotinylated) RNAor single-stranded DNA of at least 12 (preferably at least 30) bases inlength in a sequence which comprises a sequence of at least 12(preferably at least 30) contiguous bases between bases -238 and 3495,inclusive, in FIGS. 2a-2f, or such a labeled RNA or single-stranded DNAwith a sequence taken from the cDNA, described in Example 4, whichencodes an human neuronal (alpha)₂ -subunit. The use of such DNAs andRNAs as probes, to identify and isolate cDNAs coding calcium channel(alpha)₂ -subunits or to identify tissue in which (alpha)₂ -subunit mRNAis made, is clear to the skilled. In this regard, see, e.g., Example 4.

The primary strategy for cloning cDNAs encoding the (alpha)₁ and the(alpha)₂ polypeptide subunits of the DHP-sensitive calcium channels fromrabbit skeletal muscle was to screen rabbit back skeletal muscle lambdagt11 cDNA expression libraries with antibody probes specific to each ofthe proteins. See generally Ausubel et al. Current Protocols inMolecular Biology, Wiley-interscience, New York (1987); Davis et al.Basic Methods in Molecular Biology, Elsevier Science Publishing Co., NewYork (1986). Monoclonal antibodies capable of immunoprecipitating theM_(r) 155K-170K DHP receptor (alpha)₁ protein from rabbit skeletalmuscle triads have been described previously by Leung, et al. J. BiolChem. 262, 7943-7946 (1987). Polyclonal antisera specific for the(alpha)₂ polypeptide subunit was prepared in guinea pigs using SDSpolyacrylamide gel purified (alpha)₂ protein as described by Nakayama,et al. J. Biol. Chem. 262, 6572-6576 (1987). One of the (alpha)₁-specific monoclonal antibodies, designated as IIF7 by Leung, et al.supra, and the (alpha)₂ -specific polyclonal antisera were used forscreening of 1.0×10⁶ recombinant phages of an oligo-dT primed lambdagt11 cDNA library. Probes based on the Tanabe et al. (alpha)₁ -subunitcDNA sequence (Nature 328, 313-318 (1987)) could also be used toidentify clones with fragments of the (alpha)₁ -subunit cDNA.

Once a positive clone was found using an antibody-screening method, theclone was used to screen further for overlapping clones. A sequentialseries of overlapping clones was thus generated. These clones weresequenced and fragments were subcloned into either pIBI 24/25 (IBI, NewHaven, Conn.) or M13 mp18/19. In cloning the (alpha)₁ -subunit, the DNAsequence was compared to the primary sequence of the DHP receptor(alpha)₁ -subunit reported by Tanabe et al. Nucleotide differencesresulting in amino acid differences were confirmed by sequencing in bothdirections.

As pertains to the (alpha)₁ -subunit, initially, two cDNA clones whichreacted positively with the IIF7 monoclonal antibody were isolated andfound to be related by cross-hybridization.

DNA sequencing of one of these clones revealed the presence of a cDNAinsert of 453 base pairs (bp). Significantly, this insert coded for a151 amino acid open reading frame with 28% homology to a region for theElectrophorus electroplax sodium channel sequence. The cDNA insertderived from this clone was used to rescreen the lambda gt11 cDNAlibrary and a rabbit back skeletal muscle Okayama-Berg cDNA library(MacLennan, et al., Nature 316, 696-700 (1985)) to isolate overlappingcDNA clones. The cDNA clones were analyzed using the dideoxychain-termination method of Sanger to determine the entire codingsequence of the (alpha)₁ subunit of the calcium channel and arestriction map was made for comparison and orientation of DNAsequences.

An oligo-dT-primed expression cDNA library was constructed in lambdagt11, using young adult rabbit back skeletal muscle poly (A+) RNA(kindly provided by J. Robbins, University of Cincinnati) isolated inguanidine isothiocyanate (see Gubler, et al., Gene 25, 263-269 (1983);Lapeyre, et al., Gene 37, 215-220 (1985); Huynh et. al, DNA Cloning: APractical Approach, Vol. I 49-78 (IRE, Oxford, 1985)). Double-strandcDNA was synthesized and EcoRI adapters were added. After the additionof the adapters, the double-strand cDNA was size-selected on a SepharoseCL-4B or Bio-Gel A-50 m column. Fragments>1500 bp were ligated intoEcoRI digested, dephosphorylated lambda gt11. The library was packagedin vitro with Gigapack-plus, (Stratagene, San Diego, Calif.) and εnefficiency of >95% recombinants was determined by plating in thepresence of X-gal and IPTG. Two clones of a total 1×10⁶ recombinantswere identified by screening the expression library with monoclonal AbIIF7 reactive with the M_(r) 170,000 (alpha)₁ subunit of the rabbitskeletal muscle calcium channel. Positive plaques were visualized bybinding HRP-goat anti-mouse IgG followed by color development with4-chloro-1-naphthol. Each clone contained a ˜500 bp insert and wasrelated by cross-hybridization. One clone was DNA sequenced to identifyan open reading frame (nts 2847-3300) and was used to identify a 6.5 Kbtranscript by Northern analysis The 453 bp insert noted above was usedto rescreen the lambda gt11 library and 8 of 1×10⁶ clones were positive.One clone (1700 bp) extended the farthest 5' to nt 2237; its 522 bp PstIfragment, nts 2294-2816, was used to screen 1×10⁶ transformants of arabbit back skeletal muscle cDNA library constructed according to themethod of Okayama and Berg (see MacLannan, et. al., Nature 316, 696-700(1985)). Three positive clones were isolated, of which the largest (5.0Kb) extended 5' to nt ˜750. The Okayama-Berg cDNA library was rescreenedwith a 5' 250 bp (PstI)-EcoRI fragment (the PstI site is donated by theOkayama-Berg vector) (nts ˜750-1006). The longest clone isolated, of 5positives, was 5.3 Kb, extending 5' to nt ˜450. To clone the 5' end of(alpha)₁, a random primed rabbit back skeletal muscle lambda gt11 cDNAlibrary was synthesized as described above with the followingmodifications: (1) pd(N)₆ hexamers (Pharmacia, Inc. Piscathaway, N.J.)were used to random prime the first strand cDNA reaction, (2) Adapterscontaining NcoI, KpnI, and EcoRI sites:

5'-CCATGGTACCTTCGTTGACG-3'

3'-GGTACCATGGAAGCAACTGCTTAA-5'

were ligated to the double-strand cDNA as described above, and (3) thedouble-strand cDNA was size-selected on a 1 ml Bio-Gel A50 m column.Fragments>600 bp were ligated into lambda gt11. 1×10⁶ recombinants ofthis library were screened in duplicate with the 1,648 bp EcoRI/XhoIfragment corresponding to nt 1006-2653 and an oligonucleotide probespanning the initiating methionine 5'-GGGAAGCCATGGAGCCATCCTCACCCCAGG-3'.Forty clones were positive with both probes, of which one (1.55 Kb)extended 78 nts 5' of the start codon and ˜450 bp 3' of the EcoRI site.

FIGS. 1a-1j shows the 5,975 nucleotide sequence of the cDNA encoding the(alpha)₁ -subunit. There is a 5,619 nucleotide sequence reading framewhich encodes a sequence of 1,873 amino acids (FIGS. 1a-1j). Thesequence context of the designated initiation codon is consistent withthe proposed consensus sequence of Kozak, Nucleic Acids Res. 15,8125-8132 (1987). The 3' non-coding sequence of the cDNA is 234nucleotides in length, excluding the poly (dA) tract, and contains aconsensus polyadenylation signal ATTAAA (nucleotides 5832-5837) 17nucleotides upstream from the poly (dA) tract. This cDNA sequence isconsistent with an ˜6,500 nucleotide DHP receptor (alpha)₁ mRNA.Furthermore, the DNA sequence is 99.4% identical to the cDNA sequenceencoding the DHP receptor reported by Tanabe, et. al., supra. Nucleotidedifferences were identified at 33 positions, of which three, nucleotides5423, 5444 and 5504 also result in amino acid changes.

FIGS. 2a-2f also show the signal peptide of the (alpha)₂ -subunit, shownas the first 26 negatively numbered amino acids. An arrow identifies thecleavage site between the signal peptide and the mature (alpha)₂-subunit. The N-terminal amino acid sequence previously determined isshown in bold sequence (Thr(+8), Trp(+12), and Asp(+14) were notpreviously determined.) The nucleotide sequence shown was determinedfrom two clones which overlapped to span the coding sequence of the(alpha)₂ -subunit. Five nucleotide differences among individual cloneswere observed resulting in four amino acid changes. Differences occurredin the sequence at positions 169, 347, 348, 984, and a deletion of nts1858-1860. The amino acids were finally determined to be as follows: Ashat residue 31, Lys at residue 90, and a deletion of Set at residue 594.An in-frame upstream stop codon is underlined as well as the start andstop codons of an upstream short open reading frame. Three putativetransmembrane regions are enclosed in boxes. Potential N-glycosylationand phosphorylation sites are indicated as described for FIGS. 1a-1j.

The open reading frame encodes a sequence of 1,106 amino acids (FIGS.2a-2f). The previously determined NH₂ -terminal amino acid sequence ofthe (alpha)₂ protein is encoded by nucleotides 79-129 in the same openreading frame (amino acid residues 1-17, FIGS. 2a-2f). The nucleotidesequence adjacent to the designated initiating codon agrees with theproposed consensus sequence. An in-frame termination codon is presentupstream beginning at nucleotide -27. In addition, an out-of-framepotential initiation codon is located beginning at nucleotide -229 andis followed by a nonsense codon at nucleotides -179 to -181. The 5'untranslated sequence of the (alpha)₂ cDNA, 308 nucleotides clone andsequenced thus far, is unusually long. This region is extremely G+Crich, approximately 80% G+C, which is similar to other relatively long5' non-coding sequences which have been reported.

FIGS. 1a-1j show the 1,873 amino acid sequence deduced from the cDNA(SEQ. ID NO. 1) of the (alpha)₁ subunit of the rabbit skeletal musclecalcium channel. Based on the identification of a clone using the(alpha)₁ -specific IIF7 monoclonal antibody, we have determined that theprotein sequence encoded by the 453 bp cDNA insert (amino acid residues950-1,100) contains the epitope recognized by this monoclonal antibody.The complete sequence yields a calculated Mr of 212,143 for the (alpha)₁protein, in contrast to the observed Mr 155K-170K, previously reportedby others using SDS polyacrylamide gel electrophoresis. The amino acidsequence determined and reported here is 99.8% identical to thatrecently described by Tanabe et al., supra, showing three amino aciddifferences at residues 1,808 (Thr to Met), 1,815 (Ala to Val), and1,835 (Ala to Glu). The calcium channel (alpha)₁ -subunit proteincontains five potential N-glycosylation sites at Ash residues 79, 257,797, 1,464, and 1,674 and seven potential cAMP-dependent phosphorylationsites at Ser residues 687, 1,502, 1,575, 1,757, 1,772, and 1,854, andThr 1,552. Analogous to the (alpha)-subunit of the sodium channel, the(alpha)₁ -subunit of the skeletal muscle calcium channel contains fourinternal repeated sequence regions. An analysis of the hydropathyprofile of the (alpha)₁ -protein sequence reveals that each repeatcontains five hydrophobic segments and one segment with strong positivecharge. Since the (alpha)₁ -protein sequence lacks an hydrophobicamino-terminal sequence characteristic of a signal peptide, it has beenproposed that the segments of the four internally repeated regionsrepresent twenty-four transmembrane segments and that the amino-andcarboxy-termini extend intracellularly. That model is consistent withtwo of the potential glycosylation sites (Asn residues 79 and 257) beinglocalized extracellularly and all of the potential phosphorylation citesbeing localized intracellularly. This generally agrees with previousbiochemical studies suggesting that the (alpha)₁ -subunit (which hasbeen identified as the putative 1,4-dihydropyridine receptor) is notglycosylated but is phosphorylated.

FIGS. 2a-2f shows the 1,106 amino acid sequence deduced from the cDNA(SEQ ID NO: 2) of the (alpha)₂ -subunit of the rabbit skeletal musclecalcium channel. The sequence yields a calculated M_(r) of 125,018 forthis protein, in contrast to the observed M_(r) 165K-175K (undernon-reducing conditions M_(r) 135K-150K under reducing conditions)determined previously by SDS polyacrylamide gel electrophoresis. The(alpha)₂ amino acid sequence deduced here from the cDNA confirms thesequence of 17 amino acids reported earlier as supposedly that of theamino terminal 17 amino acids of the (alpha)₂ -subunit. The (alpha)₂-subunit precursor has a 26 amino acid (residues -1 to -26) signalpeptide. While this proposed signal peptide is hydrophobic and of anappropriate length characteristic of signal sequences, it is somewhatunusual in that the peptide has Glu at position-1 and the Gln atposition-12 defines a rather short central hydrophic region. The(alpha)₂ protein contains 18 potential N-glycosylation sites (Ashresidues 68, 112, 160, 300, 324, 444, 451, 580, 589, 652, 671, 758, 801,865, 872, 962, 975, and 1,005) and two potential cAMP-dependentphosphorylation sites at Thr 477 and Ser 822 (FIGS. 2a-2f).

An analysis of the (alpha)₂ protein sequence for regional hydropathyreveals that, in distinct contrast to similar analysis of the (alpha)₁protein, this protein is substantially hydrophilic, although it doescontain a number of hydrophobic regions. Further characterization of thehydrophobic regions of polarity index and hydrophobic moment analysesindicates that three segments may represent transmembrane domains of the(alpha)₂ protein. The topography of the (alpha)₂ protein is not,however, easily predicted from the deduced primary amino acid sequence.This problem is further compounded by the determination that the(alpha)₂ protein lacks significant homology with any protein in theDayhoff protein sequence database or with other known ion channel andreceptor proteins. If the proposed (alpha)₂ signal sequence is, in fact,cleaved between the Glu-residue at position -1 and the Glu residue atposition, then the amino terminus of the mature protein would beextracellular. Furthermore, assuming that the three hydrophobic segmentsfunction as transmembrane domains, and that there are only three suchdomains, the carboxyl-terminus of the (alpha)₂ protein would beintracellular. Such a transmembrane topography would be consistent with8 out of the 18 potential N-glycosylation sites being localizedextracellularly and the single potential phosphorylation site beinglocalized intracellularly. Previous biochemical studies indicate thatthe (alpha)₂ -subunit of the skeletal muscle calcium channel is notphosphorylated but is extensively glycosylated.

Rabbit and human genomic DNAs were digested with various restrictionenzymes and Southern blots of these DNAs were hybridized withradiolabeled eDNA clones specific for the (alpha)₁ -subunit or the(alpha)₂ -subunit. Under conditions of high stringency, very fewhybridizing bands were observed in rabbit genomic DNA with either the(alpha)₁ - or (alpha)₂ -specific probes. This result is consistent witha low-copy number, perhaps only a single-copy, of each of the (alpha)₁ -and (alpha)₂ -subunit genes in the rabbit genome. Southern blot of thesame DNA preparations were also probed under conditions of lowstringency with the same (alpha)₁ - and (alpha)₂ -specific probes. Whileadditional hybridizing bands were observed in rabbit genomic DNA underlow stringency conditions with both the (alpha)₁ - and (alpha)₂-specific probes, substantially greater hybridization was observed withthe (alpha)₁ -specific cDNA probes. These results suggest that the(alpha)₁ - and (alpha)₂ -subunits of the skeletal muscle DHP-sensitivecalcium channel may share significant homology with genes encoding othervoltage-dependent DHP-sensitive calcium channels, voltage-dependentcalcium channels which are not DHP-sensitive (e.g., T- and N-types), andpossibly ligand-gated calcium channels (e.g., glutamate receptor).Interestingly, hybridization bands were observed in human genomic DNAwith the (alpha)₁ -specific cDNA probes under both high and lowstringency conditions, whereas significant hybridization of (alpha)₂-specific cDNA probes were observed only under low stringencyconditions. Thus, while there are human genes homologous to the rabbit(alpha)₁ - and (alpha)₂ -subunit genes, greater evolutionary sequencedivergence may have occurred in the (alpha)₂ gene relative to the(alpha)₁ gene.

A further aspect of the invention provides for a diagnostic assay forLambert Eaton Syndrome (LES). LES is an autoimmune disease characterizedby an insufficient release of acetylcholine from motor nerve terminalswhich normally are responsive to nerve impulses. A recent publication(Kim and Neher, Science 239, 405-408 (1988)) demonstrates that IgG fromLES patients block individual voltage-dependent calcium channels andthus prevent function. A diagnostic assay for LES based on immunologicalreactivity of LES IgG with calcium channel (alpha)₂ -subunit alone or incombination with (alpha)₁ -subunit is thus provided for. For example,such an assay may be based on immunoprecipitation of LES IgG by thecalcium channels subunits of the invention.

EXAMPLE 1 Isolation of RNA for cDNA Library

On the day before RNA is isolated, prepare the following. As aprecaution, all glassware should be baked and all stock solutions in thelist immediately below should be sterilized by autoclaving.

200 ml of 0.1 NaOAc, pH 5.2, 1 mM EDTA

50 ml of 0.2M Na₂ EDTA, pH 8.0.

50 ml of 1M Tris, pH 7.5

50 ml of 3.2 Tris, pH 7.2

50 ml of 0.01M Tris (pH 8.0), 1 mM EDTA

50 ml PK buffer (0.1M Tris, pH 7.2, 50 mM NaCl, 10 mM EDTA)

50 ml of 10% SDS,

4 l of ultrapure H₂ O

On the morning of the RNA isolation, combine:

100 ml H₂ O

100 g guanidine isothiocyanate (IBI)

10.6 ml 1M Tris, pH 7.5

10.6 ml 0.2M EDTA

Stir, but do not heat above 65° C. to dissolve guanidine isothiocyanate.

Dissect young adult rabbit a cl skeletal muscle on a clean glass plateand add about 10 g of muscle tissue (cut in ˜4 mm pieces) to 50 ml ofthe guanidine isothiocyanate solution in e.g., a 100 ml Wheaton bottle.

Homogenize using "tissuemizer" from Tekman (large blade) for 10-20 sec.,or until small pieces are no longer visible.

Place in 60° H₂ O bath, add 30 ml of redistilled phenol which has beenmade 0.1% in 8-OH quinoline, 0.2% β-ME. Solution should be clear andhomogenous after this addition.

Add 30 ml of a 1:1 solution of chloroform:acetate buffer.

Shake vigorously at 60° for 10 minutes the solutions should appearopaque; if not, add sufficient chloroform:acetate until it turns milky.

Cool on ice, spin to separate phases (7000×g, 10-20 minutes)

Take off and pass it vigorously through a 22 gauge needle.

Treat with phenol:chloroform (1:1) saturated with acetate buffer.Extract aqueous layer with 3×volume of chloroform. Add 2 vol of -20°EtOH, and ppt for 1-2 hours, but no longer.

Collect precipitate; dry briefly (<5 minutes) under vacuum. Resuspend in7 ml of PK buffer made 0.2% with respect to SDS. If precipitatedevelops, heat at 65° until solution clears. Add 1.5 mg of proteinase K.

Incubate 20 minutes at 37° (if you have dried for too long, RNA will bevery difficult to get into solution and vigorous piperting will benecessary throughout the incubation).

Extract reaction with 1:1 phenol:chloroform (made 0.1% in 8-OHquinoline, 0.2% β-ME, saturate with 100 mM Tris, pH 8.5 or PK buffer pH7.7), 2×with chloroform, ppt by addition of 1/10 volume of 3.2M Tris, pH7.5 and 2 vol. of EtOH. Poly A⁺ RNA may then be isolated from the RNAmixture by well-known hybridization methods utilizing matrix-immobilizedoligo (dT).

EXAMPLE 2 cDNA Cloning Procedure

1. First Strand Synthesis

a. The following reagents and compositions are combined together andincubated on ice for 5 minutes:

    ______________________________________                                                                      Final                                                                         Concen-                                         Reagent           Volume      tration                                         ______________________________________                                        ˜5 μg poly A+ RNA, plus water                                                          to 10.5  μl                                              5X reverse transcriptase buffer                                                                 10       μl  1X                                          0.5M DTT          1        μl  10 mM                                       RNasin (24 U/μl)                                                                             2        μl  ˜IU/μl                             5X dNTPs          10       μl  1X                                          oligo dT (250 μg/ml)                                                                         5        μl  25 μg/ml                                 ______________________________________                                    

b. Next, the following three reagents are added to (a) and the mixtureis incubated at 37° C. for 60 minutes:

    ______________________________________                                        actinomycin D (600 μg/ml)                                                                     4      μl  ˜50 μg/ml                           .sup.32 P-gammadCTP (3200 Ci/mmol)                                                               2.5    μl  --                                           MMLV-reverse transcriptase                                                                       5      μl  200 U/μg RNA                              (BRL-200 U/μl)  50     μl  (total a + b)                                ______________________________________                                    

c. The following reagents are added to (b) and the mixture is incubatedat 37° C. for 30 minutes:

    ______________________________________                                        RNasin (24 U/μl) 1 μl                                                   MMLV-reverse transcriptase                                                                        3 μl                                                   (BRL-200 U/μl)                                                             ______________________________________                                    

d. Take aliquots for analysis:

1 μl at time 0 for TCA

1 μl at 90 minutes for TCA

0.5 μl at 90 minutes for gel

e. The reaction is stopped after 30 minutes adding 2 μl of 0.5M EDTA andperforming one phenol/chloroform extraction, followed by one chloroformextraction. Then 10 μl of 10M NH₄ OAc plus two volumes of ethanol areadded to precipitate the first strand.

f. To analyze the synthesis, 0.5 μl of the reaction are run on a 1.5%agarose mini-gel, the gel is photographed, dried, and placed under film(generally an overnight exposure with an intensifying screen isadequate).

g. Calculate the mass of cDNA from the percent incorporation of labelabove background. 1 μg ss cDNA=1.4% incorporation.

2. Second Strand Synthesis

a. The cDNA-RNA is spun down by centrifugation in a benchtop microfugefor 15 minutes. The pellet is washed in 95% ethanol and dried.

b. The following mixture is assembled and incubated at 12° C. for 60minutes.

    ______________________________________                                                                 Final                                                                         Concen-                                                             Volume    tration                                              ______________________________________                                        cDNA RNA, plus water                                                                           to 68   μl                                                5X 2nd strand buffer                                                                           20      μl   1X                                           10 mM β-NAD 1.5     μl   0.15 mM                                      4 mM dNTPs       5       μl    200 μM/ml                                DNA polymerase I (10 U/μl)                                                                  2.5     μl    250 U/ml                                    E. coli DNA ligase (2 U/μl)                                                                 2       μl     40 U/ml                                    RNase H (2.3 U/μl)                                                                          1       μl     23 U/ml                                                     100     μl                                                ______________________________________                                    

c. To this mix is added the following, and incubation continues at 22°C. for 60 minutes:

    ______________________________________                                        DNA polymerase I (10 U/μl)                                                                     1.5 μl                                                 E. coli DNA ligase (2 U/μl)                                                                    1.5 μl                                                 ______________________________________                                    

d. The reaction is stopped after 60 minutes by adding 4 μl of 0.5M EDTAand performing one phenol/chloroform extraction and one chloroformextraction.

e. The aqueous phase is run over a G-50 column in a short Pasteur pipetand 100 μl fractions are collected. The 500 μls containing the cDNA iscollected and pooled, and butanol extracted doom to a volume of ˜50 μl .The cDNA is precipitated by adding 10 μl of 10M NH₄ OAc plus two volumesof ethanol.

3. T4 Polymerase Reaction

a. The cDNA is spun down in a microfuge for 15 minutes. A 95% ethanolwash is performed and the cDNA pellet is dried. The dry pellet iscounted in a scintillation counter. Assume 100% efficiency of the 2ndstrand reaction, and calculate mass of double-stranded cDNA from thefirst strand calculation.

b. To the cDNA is added the following, and the mixture is incubated at37° C. for 20 minutes.

    ______________________________________                                        cDNA              +                                                           10X T4 buffer     5           μl                                           H.sub.2 O         40.75       μl                                           4 mM dNTPs        1.25        μl                                           0.1 mM DTT        2.5         μl                                           T4 polymerase (10 U/μl)                                                                      0.5         μl                                                             50          μl                                           ______________________________________                                    

c. Aliquots are taken:

0.5 μl for gel at time 0

0.5 μl for gel at 20 minutes

d. The reaction is stopped after 20 minutes by adding 2 μl of 0.5M EDTA,followed by a phenol/chloroform extraction and a chloroform extraction.

e. The aqueous phase is run over a G-50 column in a short Pasteur pipetand 100 μl fractions are collected. The 500 μls containing the cDNA iscollected and pooled, and butanol extracted down to a volume of ˜50 μl.The cDNA is precipitated by adding 10 μl of 10M NH₄ OAc plus two volumesof ethanol.

f. The 0.5 μl samples taken at time 0 and 20 minutes are run on a 1.5%agarose mini-gel, which is subsequently photographed, dried, and placedunder film.

4. Addition of EcoRI Adapters (for Insertion into Lambda gt11)

a. Oligos are synthesized having the following sequences:

20 mer: 5'-CCATGGTACCTTCGTTGACG-3'

24 mer: 3'-GGTACCATGGAAGCAACTGCTTAA-5'

b. The 20 mer is phosphorylated by combining the following reagents andincubated at 37° C. for 15 minutes.:

    ______________________________________                                        225 pmoles 20 mer    +                                                        water                6.8       μl                                          10X kinase buffer    1.2       μl                                          .sup.32 P-gammaATP (7000 Ci/mmole)                                                                 1.0       μl                                          kinase (2 U/μl)   1.0       μl                                                               10        μl                                          ______________________________________                                    

c. The following two reagents are added to above mixture and it isincubated at 37° C. for 30 minutes:

    ______________________________________                                        10 mM ATP     1          μl                                                kinase (2 U/ml)                                                                             1          μl                                                              12         μl (total b + c)                                  ______________________________________                                    

d. The enzyme is then inactivated by boiling for minutes.

e. The 24 mer is hybridized to the phosphorylated 20 mer by addition of225 pmoles of the 24 mer (plus water to bring volume to 15 μl), andincubation at 65° C. for 5 minutes. The reaction is then allowed to slowcool to room temperature.

The adapters are now present at a concentration of 15 pmoles/μl , andare ready for cDNA-vector ligation.

f. Combine the following:

    ______________________________________                                        cDNA               +                                                          hybridized adapters (15 pmol/μl)                                                              50-fold molar excess over                                                     cDNA                                                       water              16 μl                                                   10x ligase butter   2 μl                                                   ligase (10 U/μl)                                                                               2 μl                                                                      20 μl                                                   ______________________________________                                    

5. Phosphorylation of cDNA

a. The ligase is inactivated by heating the mixture to 72° C. for 15minutes.

b. The following reagents are added to the cDNA ligation reaction and itis heated at 37° C. for 30 minutes:

    ______________________________________                                        cDNA ligation reaction                                                                           20 μl                                                   water              24 μl                                                   10X kinase buffer   3 μl                                                   10 mM ATP           1 μl                                                   kinase (2 U/μl)  2 μl                                                                      50 μl                                                   ______________________________________                                    

c. The reaction is stopped by the addition of 2 μl 0.5M EDTA, followedby one phenol/chloroform extraction and one chloroform extraction.

6. Purification and Size-Selection of cDNA

a. The cDNA is run over a BIO-GEL A-50 column that has been washed with≧5 ml of TE buffer. The column has 0.8 ml bed resin in a 0.2 cm (innerdiameter)×30 cm siliconized glass tube with a glass wool plug in ayellow pipet tip at the bottom.

b. The cDNA is dried down in a speed vac to -20 μl. 2.5 μl of gelloading dye is added and the cDNA is run over the column. The countsbegin coming off after. running 200-250 μl TE buffer through the column.5 minute fractions (˜30 μl) are collected and counted in a scintillationcounter. Free adapters may begin to elute off 350-400 μl after the cDNAstarts to elude.

c. 0.5 μl of several of the collected fractions are run on a 1.5%agarose minigel. The gel is photographed, dried down, and placed underfilm.

7. Ligation of cDNA to Lambda gt11 vector

a. The fractions containing cDNA are pooled, butanol extracted down to20-30 μl, and 5 μl of 10M NH₄ OAc plus two volumes of ethanol is addedto precipitate the eDNA. It is spun in a microfuge for 15 minutes, andthen subjected to a 95% ethanol wash and dry.

b. The pellet is counted, and the mass of cDNA is calculated relative tothe mass after the second strand synthesis.

c. The cDNA is resuspended in TE (˜0.10 pmol/μl).

d. The ligation reaction contains the following, which is incubated at14°-16° C. overnight:

    ______________________________________                                        (use 1 μg of lambda gt11 vector = 0.035 pmol vector)                       ______________________________________                                        lambda gt11 (1 μg/μl)                                                                 1       μl                                                   cDNA insert           (2-4 fold molar excess of cDNA                                                over vector)                                            water         to 3    μl                                                   5X ligase buffer                                                                            1       μl                                                   ligase (10 U/μl)                                                                         1       μl                                                                 5       μl                                                   ______________________________________                                    

8. Packaging

The vector is packaged using the Gigapack in vitro packaging kitsupplied by Strategene, and following the instructions containedtherein.

    ______________________________________                                        REAGENTS                                                                      ______________________________________                                        5x RT buffer                                                                  250 mM Tris, pH 7.4                                                                           250       μl of 1M                                         375 mM KCl      375       μl of 1M                                         15 mM MgCl.sub.2                                                                              75        μl of 0.2M                                       H.sub.2 O       300       μl                                                               1000      μl                                               5X dNTPs                                                                      5 mM dATP       14.1      μl                                               3 mM dCTP       9.1       μl                                               5 mM dGTP       13.6      μl                                               5 mM dTTP       13.3      μl                                                               50        μl                                               5X 2nd Strand Buffer                                                          100 mM Tris, pH 7.5                                                                           100       μl of 1M                                         500 mM KCl      500       μl of 1M                                         50 mM (NH.sub.4).sub.2 SO.sub.4                                                               50        μl of 1M                                         25 mM MgCl.sub.2                                                                              125       μl of 0.2M                                       250 μg/ml BSA                                                                              5         μl of 50 mg/ml                                   water           220       μl                                                               1000      μl                                               10X T4 buffer                                                                 670 mM Tris, pH 8.0                                                                           670       μl of 1M                                         167 mM (NH.sub.4).sub.2 SO.sub.4                                                              167       μl of 1M                                         67 mM MgCl.sub.2                                                                              67        μl of 1M                                         H.sub.2 O       96        μl                                                               1000      μl                                               ______________________________________                                    

EXAMPLE 3 Screening cDNA Library with Antibody

Plate lambda gt11 library on Y1090 in LB agar and 50 μg/ml ampicillin.Grow overnight in 15 ml of LB, 0.2% maltose and 50 μg/ml ampicillin.Pellet the cells and resuspend in 3 ml of 10 mM MgSO₄. Plate four platesat 250,000 plaques/plate using 25 μl of phage (10,000/μl) and 300 μl ofsaid 3 ml solution of cells in 10 ml soft agar containing 50 μg/mlampicillin.

Grow at 42° C. for 2.5 hours and overlay IPTG-treated filters which weresoaked in 10 mM IPTG (Boehringer Mannhelm Biochemicals, Indianapolis,Ind.). Dry filters until just moist, lay them in the plates and incubateovernight at 37° C.

Orient the plates and spot 0.5 μl of purified DHP receptor on one plateas a positive control. Wash the filters for 10 min at room temperatureTBS (50 mM TRIS, 150 mM NaCl, pH 8.0). Wash filters in TBS, 20% FCS(filtered) for 30 min at room temp.

Incubate the filters for 2 hours in TBS, 20% FCS, anti-DHS-receptorantibody (monoclonal or polyclonal). Wash for 10 min in TBS. Transferfilters to new plates and wash for 1 min in TBS, 0.1% NP40. Wash for 10min in TBS and transfer to new plates.

Incubate for at least 1 hour with TBS, 20% FCS containing an appropriatesecond antiboby (e.g. HRP-Protein A; or HRP-goat anti-mouse IgG).

Wash filters as described above for the first antibody.

Develop the positive clones using about 40 ml/plate of4-chloro-1-naphthol reagent which is made by dissolving 60 mg of saiddeveloper in 20 ml of ice cold MeOH and mixing 4-chloro-1-naphthol(Aldrich Chemical Company, Milwaukee, Wis.) into 100 ml of TBScontaining 60 μl of 30% H₂ O₂.

EXAMPLE 4 An Human Neuronal Calcium Channel (Alpha)₂ -Subunit- EncodingcDNA

Because of the indications, mentioned supra, that human calcium channel(alpha)₂ -subunit genes had diverged somewhat from rabbit calciumchannel (alpha)₂ -subunit genes, human (alpha)₂ -subunit- encodingfragments were isolated to use as probes to screen human brain cDNAlibraries under high stringency conditions.

Thus, an EcoRI-digested human genomic Southern blot was probed underboth low and high stringency conditions with a fragment of rabbit(alpha)₂ -subunit-encoding cDNA (the fragment from nucleotide 43 tonucleotide 272 indicated in a FIGS. 2a-2f). Under low stringencyconditions, two genomic fragments were identified, of 3.0 kbp and 3.5kbp in size. Under high stringency conditions, only the 3.5 kbp fragmentmaintained a stable hybrid. These two fragments were cloned intolambda-gt11. The 3.5 kbp fragment includes a small PstI-XbaI fragment,of about 300 bp, which includes an 82 bp exon with 96.4% homology tonucleotides 102 to 183 of the sequence in FIGS. 2a-2f. This exon ispreceded by the dinucleotide AG (splice donor) and followed by thedinucleotide GT (splice acceptor), as understood in the art. The 3.0 kbpfragment includes an XbaI-BgIII fragment, of about 585 bp, whichincludes 104 bp of an exon (which includes the BgIII site at itsdownstream end) which, in the 104 bp, has 93.3% homology to nucleotides184 to 287 of the sequence in FIGS. 2a-2f. Both the 300 bp, PstI-XbaIfragment and the 585 bp, XbaI-BgIII fragments were used to probeduplicate lifts of a human basal ganglia cDNA library in lambda-gtll(the library having been obtained from the American Type CultureCollection, Rockville, Md., USA, and containing about 10⁶ independentrecombinants with an average insert size of 800-1000 bp). Three positiveclones were identified which hybridized to both probes under highstringency conditions, one with an insert size of about 1150 bp, anotherwith an insert size of about 790 bp, and the third with an insert sizeof about 670 bp. The 1150 bp insert in the one clone extended into thecoding region from about nucleotide 200 in the coding region and wasfound to have a sequence more than 90% homologous to that of thecorresponding segment of the cDNA whose sequence is presented in FIGS.2a-2f. Using the lambda genome with the 1150 bp insert as probe, anhuman brain stem eDNA library (also purchased from the American TypeCulture Collection, and having about 4×10⁶ independent recombinants withan average insert size of 800-1000 bp) was probed under high stringencyconditions. In this probing, four positive clones were identified, withinserts of about 950 bp, 1120 bp, 3000 bp and 2500 bp. Most of the 1120bp insert overlapped the 1150 bp insert of the DNA used as probe butextended somewhat upstream from the upstream end of the 1150 bp insert.The 2500 bp insert extended downstream from about 650 bp from the 5'-endof the 1120 bp insert. The DNA with the 2500 bp insert was used to againprobe the brain stem library, and a clone with a 2750 bp insert wasfound. The 2750 bp insert was found by restriction analysis andsequencing to extend in the 3'-direction beyond the translational stopsignal of a reading frame that was found to begin in the 1120 bp insertdescribed above. The 2750 bp insert and 1120 bp insert have a PvuII sitein common and have been ligated using the PvuII site to provide a cDNAthat encodes a human neuronal calcium channel (alpha)₂ -subunit. The5'-1560 bp of this cDNA have been sequenced and, as illustrated in FIGS.3a-3d, found to be 91.2% homologous with the corresponding 1575 bpsegment indicated in FIGS. 2a-2f.

The human (alpha)₂ -subunit-encoding cDNA will be subcloned into themammalian expression vector pSV2DHFR, which is available in the art, forexpression in mammalian tissue culture cells.

We obtained the human neuroblastoma cell line IMR32 from the AmericanType Culture Collection (accession no. CCL127). A northern blot analysiswas carried out on poly A⁺ RNA from this cell line using the full-lengthhuman (alpha)₂ -subunit-encoding cDNA. Under low stringency washing, asingle 8.2 kb fragment was found. The rabbit skeletal muscle (alpha)₂-encoding messenger RNA also had a size similar to 8.2 kb. While theinvention has been described herein with some specificity, theordinarily skilled in the art will recognize numerous variations andmodifications, in what is described, that are within the spirit of theinvention. Such variations and modifications are within the scope of theinvention as described in the claims herein.

Various features of the invention are also described in the following.

    __________________________________________________________________________    SEQUENCE LISTING                                                              (1) GENERAL INFORMATION:                                                      (iii) NUMBER OF SEQUENCES: 3                                                  (2) INFORMATION FOR SEQ ID NO:1:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 5975 base pairs                                                   (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                          (ii) MOLECULE TYPE: cDNA                                                      (ix) FEATURE:                                                                 (A) NAME/KEY: Coding Sequence                                                 (B) LOCATION: 79...5700                                                       (D) OTHER INFORMATION:                                                        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                       GCGGGGAACACTGGGGACGCAGGGAAGAGAGGGCCGCGGGGTGGGGGAGCAGCAGGAAGC60                GCCGTGGCCAGGGAAGCCATGGAGCCATCCTCACCCCAGGATGAGGGCCTG111                        MetGluProSerSerProGlnAspGluGlyLeu                                             1510                                                                          AGGAAGAAACAGCCCAAGAAGCCCCTGCCCGAGGTCCTGCCCAGGCCG159                           ArgLysLysGlnProLysLysProLeuProGluValLeuProArgPro                              152025                                                                        CCGCGGGCTCTGTTCTGCCTGACCCTGCAGAACCCGCTGAGGAAGGCG207                           ProArgAlaLeuPheCysLeuThrLeuGlnAsnProLeuArgLysAla                              303540                                                                        TGCATCAGCATCGTGGAATGGAAACCCTTCGAGACCATCATCCTGCTC255                           CysIleSerIleValGluTrpLysProPheGluThrIleIleLeuLeu                              455055                                                                        ACCATCTTTGCCAACTGTGTGGCCCTGGCCGTGTACCTGCCCATGCCC303                           ThrIlePheAlaAsnCysValAlaLeuAlaValTyrLeuProMetPro                              60657075                                                                      GAGGATGACAACAACTCCCTGAACCTGGGCCTGGAGAAGCTGGAGTAC351                           GluAspAspAsnAsnSerLeuAsnLeuGlyLeuGluLysLeuGluTyr                              808590                                                                        TTCTTCCTCACCGTCTTCTCCATCGAAGCCGCCATGAAGATCATCGCC399                           PhePheLeuThrValPheSerIleGluAlaAlaMetLysIleIleAla                              95100105                                                                      TACGGCTTCCTGTTCCACCAGGACGCCTACCTGCGCAGCGGCTGGAAC447                           TyrGlyPheLeuPheHisGlnAspAlaTyrLeuArgSerGlyTrpAsn                              110115120                                                                     GTGCTGGACTTCATCATCGTCTTCCTGGGGGTCTTCACGGCGATTCTG495                           ValLeuAspPheIleIleValPheLeuGlyValPheThrAlaIleLeu                              125130135                                                                     GAACAGGTCAACGTCATCCAGAGCAACACGGCCCCGATGAGCAGCAAA543                           GluGlnValAsnValIleGlnSerAsnThrAlaProMetSerSerLys                              140145150155                                                                  GGAGCCGGCCTGGACGTCAAGGCCCTGAGGGCCTTCCGTGTGCTCAGA591                           GlyAlaGlyLeuAspValLysAlaLeuArgAlaPheArgValLeuArg                              160165170                                                                     CCCCTCCGGCTGGTGTCGGGGGTGCCTAGTTTGCAGGTGGTCCTCAAC639                           ProLeuArgLeuValSerGlyValProSerLeuGlnValValLeuAsn                              175180185                                                                     TCCATCTTCAAGGCCATGCTCCCCCTGTTCCACATCGCCCTGCTCGTC687                           SerIlePheLysAlaMetLeuProLeuPheHisIleAlaLeuLeuVal                              190195200                                                                     CTCTTCATGGTCATCATCTACGCCATCATCGGGCTGGAGCTCTTCAAG735                           LeuPheMetValIleIleTyrAlaIleIleGlyLeuGluLeuPheLys                              205210215                                                                     GGCAAGATGCACAAGACCTGCTACTACATCGGGACAGACATCGTGGCC783                           GlyLysMetHisLysThrCysTyrTyrIleGlyThrAspIleValAla                              220225230235                                                                  ACAGTGGAGAATGAGAAGCCCTCGCCCTGCGCTAGGACGGGCTCGGGG831                           ThrValGluAsnGluLysProSerProCysAlaArgThrGlySerGly                              240245250                                                                     CGCCCCTGCACCATCAACGGCAGCGAGTGCCGGGGCGGCTGGCCGGGG879                           ArgProCysThrIleAsnGlySerGluCysArgGlyGlyTrpProGly                              255260265                                                                     CCCAACCACGGCATCACGCACTTCGACAACTTCGGCTTCTCCATGCTC927                           ProAsnHisGlyIleThrHisPheAspAsnPheGlyPheSerMetLeu                              270275280                                                                     ACCGTGTACCAGTGCATCACCATGGAGGGCTGGACAGATGTCCTCTAC975                           ThrValTyrGlnCysIleThrMetGluGlyTrpThrAspValLeuTyr                              285290295                                                                     TGGGTCAACGATGCCATCGGGAACGAGTGGCCCTGGATCTACTTTGTC1023                          TrpValAsnAspAlaIleGlyAsnGluTrpProTrpIleTyrPheVal                              300305310315                                                                  ACTCTCATCCTGCTGGGGTCCTTCTTCATCCTCAACCTGGTGCTGGGC1071                          ThrLeuIleLeuLeuGlySerPhePheIleLeuAsnLeuValLeuGly                              320325330                                                                     GTCCTGAGTGGGGAATTCACCAAGGAGCGGGAGAAGGCCAAGTCCAGG1119                          ValLeuSerGlyGluPheThrLysGluArgGluLysAlaLysSerArg                              335340345                                                                     GGAACCTTCCAGAAGCTGCGGGAGAAGCAGCAGCTGGAGGAGGACCTT1167                          GlyThrPheGlnLysLeuArgGluLysGlnGlnLeuGluGluAspLeu                              350355360                                                                     CGGGGCTACATGAGCTGGATCACGCAGGGCGAGGTCATGGACGTGGAG1215                          ArgGlyTyrMetSerTrpIleThrGlnGlyGluValMetAspValGlu                              365370375                                                                     GACCTGAGAGAAGGAAAGCTGTCCTTGGAAGAGGGAGGCTCCGACACG1263                          AspLeuArgGluGlyLysLeuSerLeuGluGluGlyGlySerAspThr                              380385390395                                                                  GAAAGCCTGTACGAAATCGAGGGCTTGAACAAAATCATCCAGTTCATC1311                          GluSerLeuTyrGluIleGluGlyLeuAsnLysIleIleGlnPheIle                              400405410                                                                     CGACACTGGAGGCAGTGGAACCGTGTCTTTCGCTGGAAGTGCCATGAC1359                          ArgHisTrpArgGlnTrpAsnArgValPheArgTrpLysCysHisAsp                              415420425                                                                     CTGGTGAAGTCGAGAGTCTTCTACTGGCTGGTCATCCTGATCGTGGCC1407                          LeuValLysSerArgValPheTyrTrpLeuValIleLeuIleValAla                              430435440                                                                     CTCAACACCCTGTCCATCGCCTCGGAGCACCACAACCAGCCGCTCTGG1455                          LeuAsnThrLeuSerIleAlaSerGluHisHisAsnGlnProLeuTrp                              445450455                                                                     CTGACCCACTTGCAAGACATCGCCAATCGAGTGCTGCTGTCACTCTTC1503                          LeuThrHisLeuGlnAspIleAlaAsnArgValLeuLeuSerLeuPhe                              460465470475                                                                  ACCATCGAGATGCTGCTGAAGATGTACGGGCTGGGCCTGCGCCAGTAC1551                          ThrIleGluMetLeuLeuLysMetTyrGlyLeuGlyLeuArgGlnTyr                              480485490                                                                     TTCATGTCCATCTTCAACCGCTTCGACTGCTTCGTGGTGTGCAGCGGC1599                          PheMetSerIlePheAsnArgPheAspCysPheValValCysSerGly                              495500505                                                                     ATCCTGGAGCTGCTGCTGGTGGAGTCGGGCGCCATGACGCCGCTGGGC1647                          IleLeuGluLeuLeuLeuValGluSerGlyAlaMetThrProLeuGly                              510515520                                                                     ATCTCCGTGTTGCGCTGCATCCGCCTCCTGAGGCTCTTCAAGATCACC1695                          IleSerValLeuArgCysIleArgLeuLeuArgLeuPheLysIleThr                              525530535                                                                     AAGTACTGGACGTCGCTCAGCAACCTGGTGGCCTCCCTGCTCAACTCC1743                          LysTyrTrpThrSerLeuSerAsnLeuValAlaSerLeuLeuAsnSer                              540545550555                                                                  ATCCGCTCCATCGCCTCGCTGCTGCTGCTGCTCTTCCTCTTCATCATC1791                          IleArgSerIleAlaSerLeuLeuLeuLeuLeuPheLeuPheIleIle                              560565570                                                                     ATCTTCGCCCTGCTGGGCATGCAGCTCTTCGGGGGGCGGTACGACTTC1839                          IlePheAlaLeuLeuGlyMetGlnLeuPheGlyGlyArgTyrAspPhe                              575580585                                                                     GAGGACACGGAAGTGCGACGCAGCAACTTCGACAACTTCCCCCAGGCC1887                          GluAspThrGluValArgArgSerAsnPheAspAsnPheProGlnAla                              590595600                                                                     CTCATCAGCGTCTTCCAGGTGCTGACGGGTGAGGACTGGAACTCCGTG1935                          LeuIleSerValPheGlnValLeuThrGlyGluAspTrpAsnSerVal                              605610615                                                                     ATGTACAACGGGATCATGGCCTACGGAGGCCCGTCCTACCCGGGCGTT1983                          MetTyrAsnGlyIleMetAlaTyrGlyGlyProSerTyrProGlyVal                              620625630635                                                                  CTCGTGTGCATCTATTTCATCATCCTTTTTGTCTGCGGCAACTATATC2031                          LeuValCysIleTyrPheIleIleLeuPheValCysGlyAsnTyrIle                              640645650                                                                     CTGCTGAATGTCTTCCTGGCCATCGCCGTGGACAACCTGGCCGAGGCC2079                          LeuLeuAsnValPheLeuAlaIleAlaValAspAsnLeuAlaGluAla                              655660665                                                                     GAGAGCCTGACTTCCGCGCAAAAGGCCAAGGCCGAGGAGAGGAAACGT2127                          GluSerLeuThrSerAlaGlnLysAlaLysAlaGluGluArgLysArg                              670675680                                                                     AGGAAGATGTCCAGGGGTCTCCCTGACAAGACGGAGGAGGAGAAGTCT2175                          ArgLysMetSerArgGlyLeuProAspLysThrGluGluGluLysSer                              685690695                                                                     GTGATGGCCAAGAAGCTGGAGCAGAAGCCCAAGGGGGAGGGCATCCCC2223                          ValMetAlaLysLysLeuGluGlnLysProLysGlyGluGlyIlePro                              700705710715                                                                  ACCACTGCCAAGCTCAAGGTCGATGAGTTCGAATCTAACGTCAACGAG2271                          ThrThrAlaLysLeuLysValAspGluPheGluSerAsnValAsnGlu                              720725730                                                                     GTGAAGGACCCCTACCCTTCAGCTGACTTCCCAGGGGATGATGAGGAG2319                          ValLysAspProTyrProSerAlaAspPheProGlyAspAspGluGlu                              735740745                                                                     GACGAGCCTGAGATCCCAGTGAGCCCCCGACCGCGCCCGCTGGCCGAG2367                          AspGluProGluIleProValSerProArgProArgProLeuAlaGlu                              750755760                                                                     CTGCAGCTCAAAGAGAAGGCAGTGCCCATCCCGGAAGCCAGCTCCTTC2415                          LeuGlnLeuLysGluLysAlaValProIleProGluAlaSerSerPhe                              765770775                                                                     TTCATCTTCAGTCCCACCAATAAGGTCCGTGTCCTGTGTCACCGCATC2463                          PheIlePheSerProThrAsnLysValArgValLeuCysHisArgIle                              780785790795                                                                  GTCAACGCCACCTGGTTCACCAACTTCATCCTGCTCTTCATCCTGCTC2511                          ValAsnAlaThrTrpPheThrAsnPheIleLeuLeuPheIleLeuLeu                              800805810                                                                     AGCAGTGCTGCGCTGGCCGCCGAGGACCCCATCCGGGCGGAGTCCGTG2559                          SerSerAlaAlaLeuAlaAlaGluAspProIleArgAlaGluSerVal                              815820825                                                                     AGGAATCAGATCCTTGGATATTTTGATATTGCCTTCACCTCTGTCTTC2607                          ArgAsnGlnIleLeuGlyTyrPheAspIleAlaPheThrSerValPhe                              830835840                                                                     ACTGTGGAGATTGTCCTCAAGATGACAACCTACGGCGCCTTCCTGCAC2655                          ThrValGluIleValLeuLysMetThrThrTyrGlyAlaPheLeuHis                              845850855                                                                     AAGGGCTCCTTCTGCCGCAACTACTTCAACATCCTGGACCTGCTGGTG2703                          LysGlySerPheCysArgAsnTyrPheAsnIleLeuAspLeuLeuVal                              860865870875                                                                  GTGGCCGTGTCTCTCATCTCCATGGGTCTCGAGTCCAGCACCATCTCC2751                          ValAlaValSerLeuIleSerMetGlyLeuGluSerSerThrIleSer                              880885890                                                                     GTGGTAAAGATCCTGAGAGTGCTAAGGGTGCTCCGGCCCCTGCGAGCC2799                          ValValLysIleLeuArgValLeuArgValLeuArgProLeuArgAla                              895900905                                                                     ATCAACAGAGCCAAAGGGTTGAAGCACGTGGTCCAGTGCGTGTTCGTG2847                          IleAsnArgAlaLysGlyLeuLysHisValValGlnCysValPheVal                              910915920                                                                     GCCATCCGCACCATCGGGAACATCGTCCTGGTCACCACGCTCCTGCAG2895                          AlaIleArgThrIleGlyAsnIleValLeuValThrThrLeuLeuGln                              925930935                                                                     TTCATGTTCGCCTGCATCGGTGTCCAGCTCTTCAAGGGCAAGTTCTTC2943                          PheMetPheAlaCysIleGlyValGlnLeuPheLysGlyLysPhePhe                              940945950955                                                                  AGCTGCAATGACCTATCCAAGATGACAGAAGAGGAGTGCAGGGGCTAC2991                          SerCysAsnAspLeuSerLysMetThrGluGluGluCysArgGlyTyr                              960965970                                                                     TACTATGTGTACAAGGACGGGGACCCCACGCAGATGGAGCTGCGCCCC3039                          TyrTyrValTyrLysAspGlyAspProThrGlnMetGluLeuArgPro                              975980985                                                                     CGCCAGTGGATACACAATGACTTCCACTTTGACAACGTGCTGTCGGCC3087                          ArgGlnTrpIleHisAsnAspPheHisPheAspAsnValLeuSerAla                              9909951000                                                                    ATGATGTCGCTCTTCACGGTGTCCACCTTCGAGGGATGGCCCCAGCTG3135                          MetMetSerLeuPheThrValSerThrPheGluGlyTrpProGlnLeu                              100510101015                                                                  CTGTACAGGGCCATAGACTCCAACGAGGAGGACATGGGCCCCGTTTAC3183                          LeuTyrArgAlaIleAspSerAsnGluGluAspMetGlyProValTyr                              1020102510301035                                                              AACAACCGAGTGGAGATGGCCATCTTCTTCATCATCTACATCATCCTC3231                          AsnAsnArgValGluMetAlaIlePhePheIleIleTyrIleIleLeu                              104010451050                                                                  ATTGCCTTCTTCATGATGAACATCTTTGTGGGCTTTGTCATCGTCACC3279                          IleAlaPhePheMetMetAsnIlePheValGlyPheValIleValThr                              105510601065                                                                  TTCCAGGAGCAGGGGGAGACGGAGTACAAGAACTGCGAGCTGGACAAG3327                          PheGlnGluGlnGlyGluThrGluTyrLysAsnCysGluLeuAspLys                              107010751080                                                                  AACCAGCGCCAGTGTGTGCAGTATGCCCTGAAGGCCCGCCCACTTCGG3375                          AsnGlnArgGlnCysValGlnTyrAlaLeuLysAlaArgProLeuArg                              108510901095                                                                  TGCTACATCCCCAAGAACCCATACCAGTACCAGGTGTGGTACGTCGTC3423                          CysTyrIleProLysAsnProTyrGlnTyrGlnValTrpTyrValVal                              1100110511101115                                                              ACCTCCTCCTACTTTGAATACCTGATGTTCGCCCTCATCATGCTCAAC3471                          ThrSerSerTyrPheGluTyrLeuMetPheAlaLeuIleMetLeuAsn                              112011251130                                                                  ACCATCTGCCTGGGCATGCAGCACTACCACCAGTCGGAGGAGATGAAC3519                          ThrIleCysLeuGlyMetGlnHisTyrHisGlnSerGluGluMetAsn                              113511401145                                                                  CACATCTCAGACATCCTCAATGTGGCCTTCACCATCATCTTCACGCTG3567                          HisIleSerAspIleLeuAsnValAlaPheThrIleIlePheThrLeu                              115011551160                                                                  GAGATGATTCTCAAGCTCTTGGCGTTCAAGGCCAGGGGCTATTTCGGA3615                          GluMetIleLeuLysLeuLeuAlaPheLysAlaArgGlyTyrPheGly                              116511701175                                                                  GACCCCTGGAATGTGTTCGACTTCCTGATCGTCATCGGCAGCATCATT3663                          AspProTrpAsnValPheAspPheLeuIleValIleGlySerIleIle                              1180118511901195                                                              GACGTCATCCTCAGCGAGATCGACACTTTCCTGGCCTCCAGCGGGGGA3711                          AspValIleLeuSerGluIleAspThrPheLeuAlaSerSerGlyGly                              120012051210                                                                  CTGTATTGCCTGGGTGGCGGCTGCGGGAACGTTGACCCAGACGAGAGC3759                          LeuTyrCysLeuGlyGlyGlyCysGlyAsnValAspProAspGluSer                              121512201225                                                                  GCCCGCATCTCCAGTGCCTTCTTCCGCCTGTTCCGGGTTATGAGGCTG3807                          AlaArgIleSerSerAlaPhePheArgLeuPheArgValMetArgLeu                              123012351240                                                                  ATCAAGCTGCTGAGTCGGGCCGAGGGCGTGCGCACGCTGCTGTGGACG3855                          IleLysLeuLeuSerArgAlaGluGlyValArgThrLeuLeuTrpThr                              124512501255                                                                  TTCATCAAGTCCTTCCAGGCCCTGCCCTACGTGGCCCTGCTCATCGTC3903                          PheIleLysSerPheGlnAlaLeuProTyrValAlaLeuLeuIleVal                              1260126512701275                                                              ATGCTGTTCTTCATCTACGCCGTCATCGGCATGCAGATGTTTGGAAAG3951                          MetLeuPhePheIleTyrAlaValIleGlyMetGlnMetPheGlyLys                              128012851290                                                                  ATCGCCCTGGTGGACGGGACCCAGATCAACCGCAACAACAACTTCCAG3999                          IleAlaLeuValAspGlyThrGlnIleAsnArgAsnAsnAsnPheGln                              129513001305                                                                  ACCTTCCCGCAGGCCGTGCTGCTGCTCTTCAGGTGTGCGACAGGGGAG4047                          ThrPheProGlnAlaValLeuLeuLeuPheArgCysAlaThrGlyGlu                              131013151320                                                                  GCGTGGCAAGAGATCCTGCTGGCCTGCAGCTACGGGAAGTTGTGCGAC4095                          AlaTrpGlnGluIleLeuLeuAlaCysSerTyrGlyLysLeuCysAsp                              132513301335                                                                  CCAGAGTCAGACTACGCCCCGGGCGAGGAGTACACGTGTGGCACCAAC4143                          ProGluSerAspTyrAlaProGlyGluGluTyrThrCysGlyThrAsn                              1340134513501355                                                              TTCGCCTACTACTACTTCATCAGCTTCTACATGCTCTGCGCCTTCCTG4191                          PheAlaTyrTyrTyrPheIleSerPheTyrMetLeuCysAlaPheLeu                              136013651370                                                                  ATCATCAACCTCTTCGTGGCTGTCATCATGGACAACTTTGACTACCTG4239                          IleIleAsnLeuPheValAlaValIleMetAspAsnPheAspTyrLeu                              137513801385                                                                  ACACGCGACTGGTCCATCCTGGGCCCTCACCACCTGGACGAGTTCAAG4287                          ThrArgAspTrpSerIleLeuGlyProHisHisLeuAspGluPheLys                              139013951400                                                                  GCCATCTGGGCAGAGTATGACCCAGAGGCCAAGGGGCGAATCAAGCAC4335                          AlaIleTrpAlaGluTyrAspProGluAlaLysGlyArgIleLysHis                              140514101415                                                                  CTGGACGTGGTGACCCTGCTGAGAAGGATCCAGCCCCCTCTGGGCTTC4383                          LeuAspValValThrLeuLeuArgArgIleGlnProProLeuGlyPhe                              1420142514301435                                                              GGGAAGTTCTGTCCACACCGGGTGGCCTGTAAGCGCCTGGTGGGCATG4431                          GlyLysPheCysProHisArgValAlaCysLysArgLeuValGlyMet                              144014451450                                                                  AACATGCCCCTGAACAGTGACGGCACGGTCACCTTCAATGCCACGCTC4479                          AsnMetProLeuAsnSerAspGlyThrValThrPheAsnAlaThrLeu                              145514601465                                                                  TTTGCCCTGGTGCGCACGGCCCTCAAGATCAAGACAGAAGGTAACTTC4527                          PheAlaLeuValArgThrAlaLeuLysIleLysThrGluGlyAsnPhe                              147014751480                                                                  GAGCAGGCCAACGAGGAGCTGAGGGCCATCATCAAGAAGATCTGGAAG4575                          GluGlnAlaAsnGluGluLeuArgAlaIleIleLysLysIleTrpLys                              148514901495                                                                  AGAACCAGCATGAAGCTACTGGACCAGGTCATCCCTCCCATAGGAGAT4623                          ArgThrSerMetLysLeuLeuAspGlnValIleProProIleGlyAsp                              1500150515101515                                                              GACGAGGTGACCGTGGGGAAGTTCTACGCCACATTCCTCATCCAGGAG4671                          AspGluValThrValGlyLysPheTyrAlaThrPheLeuIleGlnGlu                              152015251530                                                                  CACTTCCGGAAGTTCATGAAGCGCCAGGAGGAATATTATGGGTATCGG4719                          HisPheArgLysPheMetLysArgGlnGluGluTyrTyrGlyTyrArg                              153515401545                                                                  CCCAAGAAGGACACCGTGCAGATCCAGGCTGGGCTGCGGACCATAGAG4767                          ProLysLysAspThrValGlnIleGlnAlaGlyLeuArgThrIleGlu                              155015551560                                                                  GAGGAGGCGGCCCCTGAGATCCGCCGCACCATCTCAGGAGACCTGACC4815                          GluGluAlaAlaProGluIleArgArgThrIleSerGlyAspLeuThr                              156515701575                                                                  GCCGAGGAGGAGCTGGAGAGAGCCATGGTGGAGGCTGCGATGGAGGAG4863                          AlaGluGluGluLeuGluArgAlaMetValGluAlaAlaMetGluGlu                              1580158515901595                                                              AGGATCTTCCGGAGGACCGGAGGCCTGTTTGGCCAGGTGGACACCTTC4911                          ArgIlePheArgArgThrGlyGlyLeuPheGlyGlnValAspThrPhe                              160016051610                                                                  CTGGAAAGGACCAACTCCCTACCCCCGGTGATGGCCAACCAAAGACCG4959                          LeuGluArgThrAsnSerLeuProProValMetAlaAsnGlnArgPro                              161516201625                                                                  CTCCAGTTTGCTGAGATAGAAATGGAAGAGCTTGAGTCGCCTGTCTTC5007                          LeuGlnPheAlaGluIleGluMetGluGluLeuGluSerProValPhe                              163016351640                                                                  TTGGAGGACTTCCCTCAAGACGCAAGAACCAACCCTCTCGCTCGTGCC5055                          LeuGluAspPheProGlnAspAlaArgThrAsnProLeuAlaArgAla                              164516501655                                                                  AATACCAACAACGCCAATGCCAATGTTGCCTATGGCAACAGCAACCAT5103                          AsnThrAsnAsnAlaAsnAlaAsnValAlaTyrGlyAsnSerAsnHis                              1660166516701675                                                              AGCAACAACCAGATGTTTTCCAGCGTCCACTGTGAAAGGGAGTTCCCG5151                          SerAsnAsnGlnMetPheSerSerValHisCysGluArgGluPhePro                              168016851690                                                                  GGAGAGGCGGAGACACCGGCTGCCGGACGAGGAGCCCTCAGCCACTCC5199                          GlyGluAlaGluThrProAlaAlaGlyArgGlyAlaLeuSerHisSer                              169517001705                                                                  CACAGGGCCCTGGGACCTCACAGCAAGCCCTGTGCTGGAAAACTGAAT5247                          HisArgAlaLeuGlyProHisSerLysProCysAlaGlyLysLeuAsn                              171017151720                                                                  GGGCAGCTGGTCCAGCCGGGAATGCCCATCAACCAGGCACCTCCTGCC5295                          GlyGlnLeuValGlnProGlyMetProIleAsnGlnAlaProProAla                              172517301735                                                                  CCCTGCCAGCAGCCTAGCACAGATCCCCCAGAGCGCGGGCAGAGGAGG5343                          ProCysGlnGlnProSerThrAspProProGluArgGlyGlnArgArg                              1740174517501755                                                              ACCTCCCTGACAGGGTCTCTGCAAGACGAAGCACCCCAGAGGAGGAGC5391                          ThrSerLeuThrGlySerLeuGlnAspGluAlaProGlnArgArgSer                              176017651770                                                                  TCCGAGGGGAGCACCCCCAGGCGCCCGGCTCCTGCTACAGCTCTGCTG5439                          SerGluGlySerThrProArgArgProAlaProAlaThrAlaLeuLeu                              177517801785                                                                  ATCCAAGAGGCTCTGGTTCGAGGGGGCCTGGACACCTTGGCAGCTGAT5487                          IleGlnGluAlaLeuValArgGlyGlyLeuAspThrLeuAlaAlaAsp                              179017951800                                                                  GCTGGCTTCGTCATGGCAACAAGCCAGGCCCTGGTAGACGCCTGTCAG5535                          AlaGlyPheValMetAlaThrSerGlnAlaLeuValAspAlaCysGln                              180518101815                                                                  ATGGAACCGGAGGAAGTAGAGGTCGCAGCCACAGAGCTACTGAAAGAG5583                          MetGluProGluGluValGluValAlaAlaThrGluLeuLeuLysGlu                              1820182518301835                                                              CGAGAGTCCGTCCAGGGCATGGCCAGTGTCCCGGGAAGCCTGAGCCGC5631                          ArgGluSerValGlnGlyMetAlaSerValProGlySerLeuSerArg                              184018451850                                                                  AGGTCCTCCCTGGGCAGCCTTGACCAGGTCCAGGGCTCCCAGGAAACC5679                          ArgSerSerLeuGlySerLeuAspGlnValGlnGlySerGlnGluThr                              185518601865                                                                  CTTATTCCTCCCAGGCCGTGATGGCTGTGCAGTGTCCACATGACCAAGGCGAGGGG5735                  LeuIleProProArgPro*                                                           1870                                                                          GACAGTGCGTGCAGAAGCTCAGCCCTGCATGGCAGCCTCCCTCTGTCTCAGCCCTCCTGC5795              TGAGCTGGGGCGGTCTGGAACCGACCAGGAAGCCAGGAGCCTCCCCTGGCCAGCAAGAGG5855              CATGATTCTAAAGCATCCAGAAAGGCCTGGTCAGTGCCACTCCCCAGCAGGACATTAAAG5915              TCTCTAGGTCTGTGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA5975              (2) INFORMATION FOR SEQ ID NO:2:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 3802 base pairs                                                   (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                          (ii) MOLECULE TYPE: cDNA                                                      (ix) FEATURE:                                                                 (A) NAME/KEY: Coding Sequence                                                 (B) LOCATION: 309...3630                                                      (A) NAME/KEY: mat_peptide                                                     (B) LOCATION: 387...3626                                                      (D) OTHER INFORMATION:                                                        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                       AGAAGGGAGGGCGAGCGTGGTGTGTGCGCGCTCGGGCGCCGGCGGCACCGCCGAGGTCTG60                TTGGCAAAAGTCGCCCTTGATGGCGGCGGAGGCGAGGCAGCCGCGGCGCCGAACAGCCGA120               CGCGCGCTAGCGGGGTCCGCCCGCCCCTTTCCCAGAGCCCAGCGCCGCCGTTCGCCGCCG180               CCGCCGCCCGCCCGCGCGCCGTTCGCCGCCGCCGCCGCCCGCGGGTGGCAGCGCCGCTCG240               GTCCCCGGCCCCGGGGCCGGCTGGGGGGCGGTCGGGGCGTGTGAGGGGCTTGCTCCCAGC300               TCGCGAAGATGGCTGCGGGCCGCCCGCTGGCCTGGACGCTGACACTTTGG350                         MetAlaAlaGlyArgProLeuAlaTrpThrLeuThrLeuTrp                                    26-25- 20-15                                                                  CAGGCGTGGCTGATCCTGATCGGGCCCTCGTCGGAGGAGCCGTTCCCT398                           GlnAlaTrpLeuIleLeuIleGlyProSerSerGluGluProPhePro                              10-5-11                                                                       TCAGCCGTCACTATCAAGTCATGGGTGGATAAGATGCAAGAAGACCTG446                           SerAlaValThrIleLysSerTrpValAspLysMetGlnGluAspLeu                              5101520                                                                       GTCACACTGGCAAAAACAGCAAGTGGAGTCAATCAGCTTGTTGATATT494                           ValThrLeuAlaLysThrAlaSerGlyValAsnGlnLeuValAspIle                              253035                                                                        TATGAGAAATATCAAGATTTGTATACTGTGGAACCAAATAATGCACGT542                           TyrGluLysTyrGlnAspLeuTyrThrValGluProAsnAsnAlaArg                              404550                                                                        CAGCTGGTGGAAATTGCAGCCAGAGACATTGAGAAGCTTCTCAGCAAC590                           GlnLeuValGluIleAlaAlaArgAspIleGluLysLeuLeuSerAsn                              556065                                                                        AGATCTAAAGCCCTGGTGCGCCTGGCTTTGGAAGCAGAGAAAGTTCAA638                           ArgSerLysAlaLeuValArgLeuAlaLeuGluAlaGluLysValGln                              707580                                                                        GCAGCCCACCAATGGAGGGAAGATTTTGCAAGCAATGAAGTTGTCTAC686                           AlaAlaHisGlnTrpArgGluAspPheAlaSerAsnGluValValTyr                              859095100                                                                     TATAACGCGAAGGATGATCTTGATCCTGAAAAAAATGACAGTGAACCA734                           TyrAsnAlaLysAspAspLeuAspProGluLysAsnAspSerGluPro                              105110115                                                                     GGCAGCCAGAGGATCAAACCTGTTTTCATTGACGATGCTAACTTTAGA782                           GlySerGlnArgIleLysProValPheIleAspAspAlaAsnPheArg                              120125130                                                                     AGACAAGTATCCTATCAGCACGCAGCTGTCCATATCCCCACTGACATC830                           ArgGlnValSerTyrGlnHisAlaAlaValHisIleProThrAspIle                              135140145                                                                     TATGAAGGATCGACAATCGTGTTAAACGAACTCAACTGGACAAGTGCC878                           TyrGluGlySerThrIleValLeuAsnGluLeuAsnTrpThrSerAla                              150155160                                                                     TTAGATGACGTTTTCAAAAAAAATCGAGAGGAAGACCCTTCACTGTTG926                           LeuAspAspValPheLysLysAsnArgGluGluAspProSerLeuLeu                              165170175180                                                                  TGGCAGGTGTTTGGCAGTGCCACTGGCCTGGCCCGGTATTACCCAGCT974                           TrpGlnValPheGlySerAlaThrGlyLeuAlaArgTyrTyrProAla                              185190195                                                                     TCTCCATGGGTTGATAATAGCCGAACCCCAAACAAGATTGATCTTTAT1022                          SerProTrpValAspAsnSerArgThrProAsnLysIleAspLeuTyr                              200205210                                                                     GATGTACGCAGAAGACCATGGTACATCCAAGGTGCTGCATCCCCTAAA1070                          AspValArgArgArgProTrpTyrIleGlnGlyAlaAlaSerProLys                              215220225                                                                     GATATGCTTATTCTGGTGGATGTGAGTGGAAGCGTTAGTGGACTGACA1118                          AspMetLeuIleLeuValAspValSerGlySerValSerGlyLeuThr                              230235240                                                                     CTCAAACTCATCCGGACATCCGTCTCCGAAATGTTGGAAACCCTCTCA1166                          LeuLysLeuIleArgThrSerValSerGluMetLeuGluThrLeuSer                              245250255260                                                                  GATGATGATTTTGTGAACGTGGCTTCATTTAACAGCAATGCTCAGGAT1214                          AspAspAspPheValAsnValAlaSerPheAsnSerAsnAlaGlnAsp                              265270275                                                                     GTAAGCTGCTTTCAGCACCTTGTCCAAGCAAATGTAAGAAATAAGAAA1262                          ValSerCysPheGlnHisLeuValGlnAlaAsnValArgAsnLysLys                              280285290                                                                     GTGTTGAAAGATGCAGTGAATAATATCACAGCAAAAGGAATCACAGAT1310                          ValLeuLysAspAlaValAsnAsnIleThrAlaLysGlyIleThrAsp                              295300305                                                                     TATAAGAAGGGCTTTAGTTTTGCTTTTGAGCAGCTGCTTAATTATAAT1358                          TyrLysLysGlyPheSerPheAlaPheGluGlnLeuLeuAsnTyrAsn                              310315320                                                                     GTATCCAGAGCCAACTGCAATAAGATTATCATGTTGTTCACGGACGGA1406                          ValSerArgAlaAsnCysAsnLysIleIleMetLeuPheThrAspGly                              325330335340                                                                  GGAGAAGAGAGAGCCCAGGAGATATTTGCCAAATACAATAAAGACAAG1454                          GlyGluGluArgAlaGlnGluIlePheAlaLysTyrAsnLysAspLys                              345350355                                                                     AAAGTACGTGTATTCACATTCTCAGTTGGCCAACATAATTACGACAGA1502                          LysValArgValPheThrPheSerValGlyGlnHisAsnTyrAspArg                              360365370                                                                     GGACCTATTCAGTGGATGGCTTGCGAAAATAAAGGTTATTATTATGAA1550                          GlyProIleGlnTrpMetAlaCysGluAsnLysGlyTyrTyrTyrGlu                              375380385                                                                     ATTCCATCCATTGGAGCCATAAGAATTAATACTCAGGAATACCTAGAT1598                          IleProSerIleGlyAlaIleArgIleAsnThrGlnGluTyrLeuAsp                              390395400                                                                     GTTCTGGGAAGACCGATGGTTTTAGCAGGAGACAAAGCTAAGCAAGTC1646                          ValLeuGlyArgProMetValLeuAlaGlyAspLysAlaLysGlnVal                              405410415420                                                                  CAATGGACAAATGTGTACCTGGATGCACTGGAACTGGGACTTGTCATT1694                          GlnTrpThrAsnValTyrLeuAspAlaLeuGluLeuGlyLeuValIle                              425430435                                                                     ACTGGAACTCTTCCGGTCTTCAACATAACTGGCCAATTTGAAAATAAG1742                          ThrGlyThrLeuProValPheAsnIleThrGlyGlnPheGluAsnLys                              440445450                                                                     ACAAACTTAAAGAACCAGCTGATTCTTGGAGTGATGGGAGTTGATGTG1790                          ThrAsnLeuLysAsnGlnLeuIleLeuGlyValMetGlyValAspVal                              455460465                                                                     TCTTTGGAAGATATTAAAAGACTGACACCACGTTTTACACTCTGCCCC1838                          SerLeuGluAspIleLysArgLeuThrProArgPheThrLeuCysPro                              470475480                                                                     AATGGCTACTATTTTGCAATTGATCCTAATGGTTATGTGTTATTACAT1886                          AsnGlyTyrTyrPheAlaIleAspProAsnGlyTyrValLeuLeuHis                              485490495500                                                                  CCAAATCTTCAGCCAAAGCCTATTGGTGTAGGTATACCAACAATTAAT1934                          ProAsnLeuGlnProLysProIleGlyValGlyIleProThrIleAsn                              505510515                                                                     TTGAGAAAAAGGAGACCCAATGTTCAGAACCCCAAATCTCAGGAGCCA1982                          LeuArgLysArgArgProAsnValGlnAsnProLysSerGlnGluPro                              520525530                                                                     GTGACATTGGATTTCCTCGATGCAGAGTTGGAGAATGACATTAAAGTG2030                          ValThrLeuAspPheLeuAspAlaGluLeuGluAsnAspIleLysVal                              535540545                                                                     GAGATTCGAAATAAAATGATCGATGGAGAAAGTGGAGAAAAAACATTC2078                          GluIleArgAsnLysMetIleAspGlyGluSerGlyGluLysThrPhe                              550555560                                                                     AGAACTCTGGTTAAATCTCAAGATGAGAGATATATTGACAAAGGAAAC2126                          ArgThrLeuValLysSerGlnAspGluArgTyrIleAspLysGlyAsn                              565570575580                                                                  AGGACATACACGTGGACTCCTGTCAACGGCACAGATTATAGCAGTTTG2174                          ArgThrTyrThrTrpThrProValAsnGlyThrAspTyrSerSerLeu                              585590595                                                                     GCCTTGGTATTACCAACCTACAGTTTTTACTATATAAAAGCCAAAATA2222                          AlaLeuValLeuProThrTyrSerPheTyrTyrIleLysAlaLysIle                              600605610                                                                     GAAGAGACAATAACTCAGGCCAGATATTCAGAAACACTGAAACCGGAT2270                          GluGluThrIleThrGlnAlaArgTyrSerGluThrLeuLysProAsp                              615620625                                                                     AATTTTGAAGAATCTGGCTACACATTCCTAGCACCAAGAGATTACTGC2318                          AsnPheGluGluSerGlyTyrThrPheLeuAlaProArgAspTyrCys                              630635640                                                                     AGTGACCTTAAACCTTCAGATAATAACACTGAATTTCTTTTAAATTTC2366                          SerAspLeuLysProSerAspAsnAsnThrGluPheLeuLeuAsnPhe                              645650655660                                                                  AATGAGTTTATTGATAGAAAAACTCCAAACAACCCATCCTGTAATACA2414                          AsnGluPheIleAspArgLysThrProAsnAsnProSerCysAsnThr                              665670675                                                                     GACTTGATTAATAGAGTCTTGCTGGATGCAGGCTTTACAAATGAACTT2462                          AspLeuIleAsnArgValLeuLeuAspAlaGlyPheThrAsnGluLeu                              680685690                                                                     GTTCAAAATTACTGGAGTAAGCAGAAGAATATCAAGGGAGTGAAAGCA2510                          ValGlnAsnTyrTrpSerLysGlnLysAsnIleLysGlyValLysAla                              695700705                                                                     CGGTTTGTTGTGACTGATGGTGGGATTACCAGAGTTTATCCCAAAGAG2558                          ArgPheValValThrAspGlyGlyIleThrArgValTyrProLysGlu                              710715720                                                                     GCTGGAGAAAATTGGCAGGAAAACCCAGAGACATATGAAGACAGCTTC2606                          AlaGlyGluAsnTrpGlnGluAsnProGluThrTyrGluAspSerPhe                              725730735740                                                                  TATAAAAGGAGCCTCGATAATGATAACTACGTTTTCACTGCTCCCTAC2654                          TyrLysArgSerLeuAspAsnAspAsnTyrValPheThrAlaProTyr                              745750755                                                                     TTTAACAAAAGTGGACCTGGGGCCTATGAGTCAGGCATTATGGTAAGC2702                          PheAsnLysSerGlyProGlyAlaTyrGluSerGlyIleMetValSer                              760765770                                                                     AAAGCTGTAGAAATATATATCCAAGGAAAACTTCTTAAACCTGCAGTT2750                          LysAlaValGluIleTyrIleGlnGlyLysLeuLeuLysProAlaVal                              775780785                                                                     GTTGGAATTAAAATTGATGTAAATTCTTGGATAGAGAATTTCACCAAA2798                          ValGlyIleLysIleAspValAsnSerTrpIleGluAsnPheThrLys                              790795800                                                                     ACTTCAATCAGGGATCCGTGTGCTGGTCCAGTTTGTGACTGCAAACGA2846                          ThrSerIleArgAspProCysAlaGlyProValCysAspCysLysArg                              805810815820                                                                  AACAGTGATGTAATGGATTGTGTGATTCTAGATGACGGTGGGTTTCTT2894                          AsnSerAspValMetAspCysValIleLeuAspAspGlyGlyPheLeu                              825830835                                                                     TTGATGGCCAACCATGATGATTATACCAATCAGATTGGAAGATTCTTT2942                          LeuMetAlaAsnHisAspAspTyrThrAsnGlnIleGlyArgPhePhe                              840845850                                                                     GGAGAGATTGATCCAAGCTTGATGAGACACCTGGTCAATATATCAGTT2990                          GlyGluIleAspProSerLeuMetArgHisLeuValAsnIleSerVal                              855860865                                                                     TATGCCTTTAACAAATCTTATGATTATCAGTCGGTGTGTGAACCTGGT3038                          TyrAlaPheAsnLysSerTyrAspTyrGlnSerValCysGluProGly                              870875880                                                                     GCTGCGCCAAAGCAGGGAGCAGGGCACCGCTCGGCTTATGTGCCATCA3086                          AlaAlaProLysGlnGlyAlaGlyHisArgSerAlaTyrValProSer                              885890895900                                                                  ATAGCAGACATACTGCAGATTGGATGGTGGGCCACTGCTGCTGCCTGG3134                          IleAlaAspIleLeuGlnIleGlyTrpTrpAlaThrAlaAlaAlaTrp                              905910915                                                                     TCTATTCTTCAGCAGTTTCTGTTGAGTTTGACTTTTCCACGGCTCCTT3182                          SerIleLeuGlnGlnPheLeuLeuSerLeuThrPheProArgLeuLeu                              920925930                                                                     GAGGCAGCTGATATGGAGGATGACGACTTCACTGCCTCCATGTCAAAG3230                          GluAlaAlaAspMetGluAspAspAspPheThrAlaSerMetSerLys                              935940945                                                                     CAGAGCTGCATCACTGAGCAAACCCAGTATTTCTTCGATAATGACAGC3278                          GlnSerCysIleThrGluGlnThrGlnTyrPhePheAspAsnAspSer                              950955960                                                                     AAATCGTTCAGTGGGGTATTAGACTGTGGGAATTGTTCCAGAATCTTT3326                          LysSerPheSerGlyValLeuAspCysGlyAsnCysSerArgIlePhe                              965970975980                                                                  CATGTAGAAAAGCTCATGAACACCAATTTAATATTCATAATGGTAGAG3374                          HisValGluLysLeuMetAsnThrAsnLeuIlePheIleMetValGlu                              985990995                                                                     AGCAAGGGGACATGTCCCTGTGACACACGGCTGCTCATACAAGCAGAG3422                          SerLysGlyThrCysProCysAspThrArgLeuLeuIleGlnAlaGlu                              100010051010                                                                  CAAACTTCTGATGGACCAGATCCTTGTGATATGGTTAAGCAACCCAGA3470                          GlnThrSerAspGlyProAspProCysAspMetValLysGlnProArg                              101510201025                                                                  TATCGAAAAGGGCCAGATGTCTGCTTTGACAACAATGTCCTGGAGGAT3518                          TyrArgLysGlyProAspValCysPheAspAsnAsnValLeuGluAsp                              103010351040                                                                  TATACTGACTGCGGTGGGGTCTCTGGATTAAATCCTTCCCTGTGGTCC3566                          TyrThrAspCysGlyGlyValSerGlyLeuAsnProSerLeuTrpSer                              1045105010551060                                                              ATCATCGGGATACAGTTTGTACTGCTTTGGCTGGTTTCTGGCAGCAGA3614                          IleIleGlyIleGlnPheValLeuLeuTrpLeuValSerGlySerArg                              106510701075                                                                  CACTGCCTGTTATGACCTTCTAAAACCAAATCTCCATAATTAAACTCCAGACCCTG3670                  HisCysLeuLeu*                                                                 1080                                                                          CCACAACATGATCCCTCCGTTATGTTAAAGTAGGGTCAACTGTTAAATCAGAACATTAGC3730              TGGGCCTCTGCCATGGCAGAGCCCTAAGGCGCAGACTCATCAGGCACCCACTGGCTGCAT3790              GTCAGGGTGTCC3802                                                              (2) INFORMATION FOR SEQ ID NO:3:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 1560 base pairs                                                   (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: unknown                                                         (ii) MOLECULE TYPE: Genomic DNA                                               (ix) FEATURE:                                                                 (A) NAME/KEY: Coding Sequence                                                 (B) LOCATION: 35...1558                                                       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                       GGGCGGGGGAGGGGGATTGATCTTCGATCGCAAGATGGCTGCTGGCTGCCTGCTG55                     MetAlaAlaGlyCysLeuLeu                                                         15                                                                            GCCTTGACTCTGACACTTTTCCAATCTTTGCTCATCGGCCCCTCGTCG103                           AlaLeuThrLeuThrLeuPheGlnSerLeuLeuIleGlyProSerSer                              101520                                                                        GAGGAGCCGTTCCCTTCGGCCGTCACTATCAAATCATGGGTGGATAAG151                           GluGluProPheProSerAlaValThrIleLysSerTrpValAspLys                              253035                                                                        ATGCAAGAAGACCTTGTCACACTGGCAAAAACAGCAAGTGGAGTCAAT199                           MetGlnGluAspLeuValThrLeuAlaLysThrAlaSerGlyValAsn                              40455055                                                                      CAGCTTGTTGATATTTATGAGAAATATCAAGATTTGTATACTGTGGAA247                           GlnLeuValAspIleTyrGluLysTyrGlnAspLeuTyrThrValGlu                              606570                                                                        CCAAATAATGCACGCCAGCTGGTAGAAATTGCAGCCAGGGATATTGAG295                           ProAsnAsnAlaArgGlnLeuValGluIleAlaAlaArgAspIleGlu                              758085                                                                        AAACTTCTGAGCAACAGATCTAAAGCCCTGGTGAGCCTGGCATTGGAA343                           LysLeuLeuSerAsnArgSerLysAlaLeuValSerLeuAlaLeuGlu                              9095100                                                                       GCGGAGAAAGTTCAAGCAGCTCACCAGTGGAGAGAAGATTTTGCAAGC391                           AlaGluLysValGlnAlaAlaHisGlnTrpArgGluAspPheAlaSer                              105110115                                                                     AATGAAGTTGTCTACTACAATGCAAAGGATGATCTCGATCCTGAGAAA439                           AsnGluValValTyrTyrAsnAlaLysAspAspLeuAspProGluLys                              120125130135                                                                  AATGACAGTGAGCCAGGCAGCCAGAGGATAAAACCTGTTTTCATTGAA487                           AsnAspSerGluProGlySerGlnArgIleLysProValPheIleGlu                              140145150                                                                     GATGCTAATTTTGGACGACAAATATCTTATCAGCACGCAGCAGTCCAT535                           AspAlaAsnPheGlyArgGlnIleSerTyrGlnHisAlaAlaValHis                              155160165                                                                     ATTCCTACTGACATCTATGAGGGCTCAACAATTGTGTTAAATGAACTC583                           IleProThrAspIleTyrGluGlySerThrIleValLeuAsnGluLeu                              170175180                                                                     AACTGGACAAGTGCCTTAGATGAAGTTTTCAAAAAGAATCGCGAGGAA631                           AsnTrpThrSerAlaLeuAspGluValPheLysLysAsnArgGluGlu                              185190195                                                                     GACCCTTCATTATTGTGGCAGGTTTTTGGCAGTGCCACTGGCCTAGCT679                           AspProSerLeuLeuTrpGlnValPheGlySerAlaThrGlyLeuAla                              200205210215                                                                  CGATATTATCCAGCTTCACCATGGGTTGATAATGGTAGAACTCCAAAT727                           ArgTyrTyrProAlaSerProTrpValAspAsnGlyArgThrProAsn                              220225230                                                                     ATGATTGACCTTTATGATGTACGCAGAAGACCATGGTACATCCAAGGA775                           MetIleAspLeuTyrAspValArgArgArgProTrpTyrIleGlnGly                              235240245                                                                     GCTGCATCTCCTAAAGACATGCTTATTCTGGTGGATGTGAGTGGAAGT823                           AlaAlaSerProLysAspMetLeuIleLeuValAspValSerGlySer                              250255260                                                                     GTTAGTGGATTGACACTTAAACTGATCCGAACATCTGTCTCCGAAATG871                           ValSerGlyLeuThrLeuLysLeuIleArgThrSerValSerGluMet                              265270275                                                                     TTAGAAACCCTCTCAGATGATGATTTCGTGAATGTAGCTTCATTTAAC919                           LeuGluThrLeuSerAspAspAspPheValAsnValAlaSerPheAsn                              280285290295                                                                  AGCAATGCTCAGGATGTAAGCTGTTTTCAGCACCTTGTCCAAGCAAAT967                           SerAsnAlaGlnAspValSerCysPheGlnHisLeuValGlnAlaAsn                              300305310                                                                     GTAAGAAATAAAAAAGTGTTGAAAGACGCGGTGAATAATATCACAGCC1015                          ValArgAsnLysLysValLeuLysAspAlaValAsnAsnIleThrAla                              315320325                                                                     AAAGGAATTACAGATTATAAGAAGGGCTTTAGTTTTGCTTTTGAACAG1063                          LysGlyIleThrAspTyrLysLysGlyPheSerPheAlaPheGluGln                              330335340                                                                     CTGCTTAATTATAATGTTTCCAGAGCAAACTGCAATAAGATTATTATG1111                          LeuLeuAsnTyrAsnValSerArgAlaAsnCysAsnLysIleIleMet                              345350355                                                                     CTATTCACGGATGGAGAAGAGAGAGCCCAGGAGATATTTAACAAATAC1159                          LeuPheThrAspGlyGluGluArgAlaGlnGluIlePheAsnLysTyr                              360365370375                                                                  AATAAAGATAAAAAACTACCTGTATTCACCTTCTCAGTTGGTCAACAC1207                          AsnLysAspLysLysLeuProValPheThrPheSerValGlyGlnHis                              380385390                                                                     AATTATGACAGAGGACCTATTCAGTGGATGGCCTGTGAAAACAAAGGT1255                          AsnTyrAspArgGlyProIleGlnTrpMetAlaCysGluAsnLysGly                              395400405                                                                     TATTATTATGAAATTCCTTCCATTGGTGCAATAAGAATCAATACTCAG1303                          TyrTyrTyrGluIleProSerIleGlyAlaIleArgIleAsnThrGln                              410415420                                                                     GAATATTTGGATGTTTTGGGAAGACCAATGGTTTTAGCAGGAGACAAA1351                          GluTyrLeuAspValLeuGlyArgProMetValLeuAlaGlyAspLys                              425430435                                                                     GCTAAGCAAGTCCAATGGACAAATGTGTACCTGGATGCATTGGAACTG1399                          AlaLysGlnValGlnTrpThrAsnValTyrLeuAspAlaLeuGluLeu                              440445450455                                                                  GGACTTGTCATTACTGGAACTCTTCCGGTCTTCAACATAACCGGCCAA1447                          GlyLeuValIleThrGlyThrLeuProValPheAsnIleThrGlyGln                              460465470                                                                     TTTGAAAATAAGACAAACTTAAAGAACCAGCTGATTCTTGGTGTGATG1495                          PheGluAsnLysThrAsnLeuLysAsnGlnLeuIleLeuGlyValMet                              475480485                                                                     GGAGTAGATGTGTCTTTGGAAGATATTAAAAGACTGACACCACGTTTT1543                          GlyValAspValSerLeuGluAspIleLysArgLeuThrProArgPhe                              490495500                                                                     ACACTGTGCCCCAATGG1560                                                         ThrLeuCysProAsn                                                               505                                                                           __________________________________________________________________________

What is claimed is:
 1. An isolated single-stranded nucleic acid having asequence which is:(a) a fragment of the sequence shown in SEQ ID NO: 2comprising at least 12 contiguous bases of the sequence from nucleotides282 to 3627 of SEQ ID NO: 2, or (b) the complement of the sequence of(a).
 2. An isolated single-stranded nucleic acid having a sequence whichis:(a) a fragment of the sequence shown in SEQ ID NO: 3 comprising atleast 12 contiguous bases of SEQ ID NO: 3, or (b) the complement of thesequence of (a).
 3. An isolated single-stranded nucleic acid comprisinga sequence which is:(a) a fragment of the sequence shown in SEQ ID NO: 2comprising at least 30 contiguous bases of the sequence from nucleotides71 to 3802 of SEQ ID NO: 2, or (b) the complement of the sequence of(a).
 4. An isolated single-stranded nucleic acid comprising a sequencewhich is:(a) a fragment of the sequence shown in SEQ ID NO: 3 comprisingat least 30 contiguous bases of SEQ ID NO: 3, or (b) the complement ofthe sequence of (a).
 5. A nucleic acid of claim 1 that is detectablylabeled.
 6. A nucleic acid of claim 2 that is detectably labeled.
 7. Anucleic acid of claim 3 that is detectably labeled.
 8. A nucleic acid ofclaim 4 that is detectably labeled.
 9. A nucleic acid of claim 5 that islabeled with ³² P.
 10. A nucleic acid of claim 6 that is labeled with ³²P.
 11. A nucleic acid of claim 7 that is labeled with ³² P.
 12. Anucleic acid of claim 8 that is labeled with ³² P.
 13. A method foridentifying a nucleic acid encoding all or part of a calcium channel α₂subunit, comprising the steps ofcontacting a sample of DNA or RNA withthe nucleic acid of claim 1, and identifying DNA or RNA present in thesample which hybridizes under conditions of high or low stringency withthe nucleic acid.
 14. A method for identifying a nucleic acid encodingall or part of a calcium channel α₂ subunit, comprising the stepsofcontacting a sample of DNA or RNA with the nucleic acid of claim 2,and identifying DNA or RNA present in the sample which hybridizes underconditions of high or low stringency with the nucleic acid.
 15. A methodfor identifying a nucleic acid encoding all or part of a calcium channelα₂ subunit, comprising the steps ofcontacting a sample of DNA or RNAwith the nucleic acid of claim 3, and identifying DNA or RNA present inthe sample which hybridizes under conditions of high or low stringencywith the nucleic acid.
 16. A method for identifying a nucleic acidencoding all or part of a calcium channel α₂ subunit, comprising thesteps ofcontacting a sample of DNA or RNA with the nucleic acid of claim4, and identifying DNA or RNA present in the sample which hybridizesunder conditions of high or low stringency with the nucleic acid.
 17. Anisolated nucleic acid molecule comprising at least 30 contiguous basepairs of the sequence set forth in SEQ ID No. 2 between nucleotides71-3802.
 18. An isolated nucleic acid molecule comprising at least 30contiguous base pairs of the sequence set forth in SEQ ID No. 3.